Health Related Quality of Life among Women with Advanced Breast Cancer : Issues of measurement, clinical significance and personal meaning by Luoma, Minna-Liisa
 HELSINGIN YLIOPISTON   UNIVERSITY OF HELSINKI 
PSYKOLOGIAN LAITOKSEN   DEPARTMENT OF PSYCHOLOGY 
TUTKIMUKSIA N:O 24  RESEARCH REPORTS N:O 24 
 
 
 
HEALTH RELATED QUALITY OF LIFE AMONG 
WOMEN WITH ADVANCED BREAST CANCER 
Issues of measurement, clinical significance and personal meaning 
 
 
Minna-Liisa Luoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
Academic dissertation to be publicly discussed, by due permission of the  
Faculty of Behavioural Sciences at the University of Helsinki, 
 in lecture room 1 at the Department of Psychology, 
 on the 19th of May, 2004, at 12 o’clock. 
  
Helsinki 2004 
Supervisors:
Docent Liisa Hakamies- Blomqvist, Ph.D. 
Department of Psychology, University of Helsinki 
Finland 
Professor Carl Blomqvist, Ph.D, MD,   
Department of Oncology, Uppsala University 
Sweden 
Reviewers:     Professor Juhani Julkunen Ph.D,  
Department of Psychology, University of Helsinki 
Finland 
  Docent Arja R.Aro, Ph.D,  
Department of Epidemiology and Health Promotion 
The Finnish National Public Health Institute 
  Finland 
Opponent: Associate Professor Yvonne Brandberg Ph.D  
  Department of Oncology-pathology. Karolinska Institutet 
   Sweden. 
ISSN 0781-8254
ISBN 952-10-1834-8 (paperback)
ISBN 952-10-1824-0 (PDF) (http://www.ethesis/helsinki.fi)
Helsinki 2004
Yliopistopaino
To  Henri 
Markus 

LEVINNYTTÄ RINTASYÖPÄÄ SAIRASTAVIEN POTILAIDEN TERVEYTEEN 
LIITTYVÄ ELÄMÄNLAATU 
 
TIIVISTELMÄ 
Terveyteen liittyvä elämänlaatu on subjektiivinen, yksilön kokemusmaailmaa kuvaava 
moniulotteinen käsite, jolla tarkoitetaan ihmisen kokemusta terveydentilastaan sekä siihen 
liittyvästä fyysisistä, psyykkisistä ja sosiaalisista tekijöistä. Levinnyt rintasyöpä on 
parantumaton sairaus ja näin ollen sen hoidon ensisijaisena tavoitteena on oireiden 
lievittäminen ja elämänlaadun kohottaminen. 
Tässä tutkimuksessa tarkasteltiin levinnyttä rintasyöpää sairastavien potilaiden 
elämänlaatua psykologisessa ja lääketieteellisessä viitekehyksessä. Tutkimuksessa 
verrattiin kahden eri solusalpaajahoidon (doketakseli vs. Methotreksaatti-Fluorourasiili) 
elämänlaatuvaikutuksia. Tutkittiin, kuinka elämänlaatu muuttuu hoitojen edetessä sekä 
mikä on lääkäreiden arvioimien sivuvaikutusten ja fyysisen kunnon yhteys potilaiden 
kokemaan elämänlaatuun. Selvitettiin myös, voiko elämänlaatumittauksilla ennustaa 
kliinisiä vastemuuttujia: hoitovasteen ja elämän pituutta, sekä osoitettiin 
elämänlaatumittausten ajoituksen kontrolloinnin merkitys. Näiden lisäksi laadullista 
haastatteluaineistoa hyödyntäen selvitettiin potilaiden elämänlaadun yksilöllisiä 
merkityssisältöjä.  
Tutkimustulokset osoittivat, että hoitoryhmien välillä ei ole merkittäviä elämänlaatueroja. 
Fyysinen kunto ja hoidon sivuvaikutukset selittivät vain pienen osan elämänlaadun 
vaihtelusta. Lähtötason elämänlaatumuuttujista ainoastaan kivut ennustivat 
elämänpituutta. Muut elämänlaatumuuttujat eivät ennustaneet hoitovastetta, elämän 
pituutta eikä myöskään muutos lähtötason elämänlaadussa ennustanut em. asioita. 
Virheellisesti ja oikein ajoitettujen elämänlaatumittausten välillä havaittiin tilastollisesti ja 
kliinisesti merkitseviä eroja. Näin ollen tutkimus osoitti empiirisesti 
elämänlaatumittausten ajoituksen kontrolloinnin tärkeyden. Laadullisen aineiston 
analyysistä nousi kolme keskeistä metateemaa, jotka määrittivät potilaiden kokemusta 
elämänlaadusta: 1) autonomian tunne (ts. tunne siitä, että mielihyvän tuottaminen on 
omassa hallussa) 2) sairauden myötä tullut kokemus omasta henkisestä kasvusta sekä 3) 
toivon merkitys potilaan elämänlaadulle.  
Yhteenvetona voidaan todeta, että elämänlaadun mittaamisesta kliinisten 
lääkeainetutkimusten yhteydessä voitaisiin saada jatkossa yhä suurempi hyöty mikäli 
tutkimukset toteutetaan menetelmällisesti perustellusti sekä yhä enenevässä määrin 
hyödyntäen sekä laadullista että määrällistä tutkimusotetta. 
 
 Avainsanat: terveyteen liittyvä elämänlaatu, rintasyöpä, laadullinen, EORTC, merkitys 
 
 
ABSTRACT  
Health Related Quality of Life (HRQoL) is understood in this study as a subjective and 
multidimensional concept, the main dimensions being physical state, psychological well-
being, social relations and functional capacity. In the absence of curative therapies, the 
therapy goals for patients with advanced breast cancer include the prolongation of 
survival, the alleviation of symptoms, and HRQoL. Therefore, the efficacy of therapeutic 
interventions should be evaluated in terms of their effect on both the quantity and quality 
of life. The purpose of the present study was to investigate HRQoL among patients with 
advanced breast cancer.  The QoL effects of two different treatments were compared.  
Specific emphasis was placed on comparing the patients’ HRQoL over time, on the 
relationship between toxicity variables, physical performance and HRQoL, on assessing 
the prognostic value of HRQoL in terms of overall survival and time to disease 
progression, and on the importance of the exact timing of the HRQoL assessments. 
Furthermore, qualitative methods were used to gain a deeper understanding of personal 
meanings related to the experience and treatment of  cancer.  
The participants of the study were, 283 patients with metastatic breast cancer, who were 
randomly assigned either docetaxel (T) or sequential methotrexate and 5-fluorouracil (M-
F) treatment. EORTC QLQ-C30 was used to measure  HRQoL. The HRQoL data and the 
clinical data were merged.    
 The results of the study showed no major advantage of either treatment over the other. In 
addition, most of the variance in HRQoL could not be explained by treatment toxicity and 
physical performance as assessed by the physician. There was only mild to moderate 
correlation between the physician-assessed toxicity and the patient-assessed toxicity 
variables. Pain did have a prognostic value for the patients’ overall survival.  However, no 
other HRQoL variables were shown to be significant prognostic factors for treatment 
response or for overall survival. Furthermore, the patients’ change scores from the 
baseline did not predict either survival or time to disease progression. Erroneous timing 
affected the HRQoL findings in both treatment groups. There were statistically and 
clinically significant differences between the responses to the ill-timed and the correctly 
timed questionnaires at baseline and over time. Thus, the study demonstrated the 
importance of correct timing in QoL assessment.   
From the results of the qualitative study, three dominant themes of personal experience 
emerged over the normative psychometric dimensions of HRQoL: ensuring feelings of 
autonomy by controlling the illness experience, experienced personal growth, and hope.  
In summary, in future assessments of and research in HRQoL, it would be useful to 
complement traditional psychometric methods with more individualised qualitative 
methods.
keywords: Health Related Quality of Life, advanced breast cancer, qualitative, EORTC, 
prognostic, meaning, timing, toxicity 
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1 INTRODUCTION 
1.1 Quality of life 
The search term “Quality of Life” in PsycINFO retrieves in 13 578 citations; by 
adding cancer, 1018 citations are listed and, by adding breast cancer only 244 are 
found citations. The corresponding figures in Medline are 58 186 citations for 
Quality of life; with cancer, 14 610 citations are given, while breast cancer only 
retrieves 2 091 citations. The Quality of life is in vogue; however, there is no 
consensus on what it really is. Quality of life has been especially widely studied 
among patients with chronic illnesses in which the condition of the patient can be 
improved by medical treatment but cannot be restored to normal functionality. The 
incorporation of this concept means that not only are the cure and survival of the 
patients important, but also that their well-being must be considered. This is of 
particular interest in cancer care in which the treatments are often uncomfortable, 
debilitating and not curative. 
 
 1.2  Health Related Quality of Life (HRQoL) 
The growing use of HRQoL for appraisal in medical interventions has created a 
need for the clarification of this concept. The World Health Organisation has 
defined health “as not merely the absence of disease or infirmity, but a state of 
complete physical, mental and social well-being (WHO, 1958). The WHO’s 
definition is widely used and strongly supports the multidimensional aspects of 
health. This definition has influenced the notion of HRQoL as a multidimensional 
concept.  
 
In the literature it is widely accepted that there is no generally agreed upon 
definition of HRQoL. However, there is there is wide agreement that  HRQoL is 
subjective in the sense that it should be assessed by individuals themselves and that 
(2) it has a multidimensional structure.   
 
There are several suggestions about how this multidimensionality of HRQoL could 
be incorporated into its definition. One of the most recent definitions of HRQoL is 
the WHOQOL (World Health Organisation Quality of Life Assesment) group’s 
definition of QoL as an “individual’s perception of their position in life in the 
context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns. It is a wide-ranging concept affected in 
2a complex way by the person’s physical health, psychological state, level of 
independence, social relationships and their relationship to the salient features of 
their environment” ("The World Health Organization Quality of Life Assessment 
(WHOQOL): development and general psychometric properties," 1998). 
Cella and colleagues (1990) have proposed a definition of HRQoL, which 
incorporates individual preferences into the level of impairment. According to them 
“ QoL refers to patients’ appraisal of and satisfaction with their current level of 
functioning compared to what they perceive to be possible or ideal”.  This 
definition stresses the individual appraisal of the advantages and disadvantages of 
treatments and therefore provides information on whether or not the disability is 
tolerable (Cella & Tulsky, 1990). According to Pandey (2002) “ HRQoL refers to 
the psychosocial, emotional and physical outcome of healthcare treatments as 
perceived by the patient. Patients interpret their feelings of well-being using 
expectations, experience and religious or community beliefs. Each of these may 
vary and depends on patients’ attitude and specific therapeutic intervention” 
(Pandey et al., 2002). This is a typical example of a psychometric-driven definition 
of HRQoL in which unobservable constructs (physical, psychosocial and 
emotional) are measured by a collection of representative questions, as Pandley 
also has done.
The quality of life, in a general sense, reflects the ways in which a person’s mental, 
social and physical well-being are evidenced in his or her everyday life.  In primary 
HRQoL dimensions, physical functioning refers to one’s ability to perform various 
activities at the most basic level of daily living, such as walking and dressing 
oneself, self-care activities or household tasks. Social functioning typically refers to 
a person’s ability to interact with family and friends and to maintain social roles. 
Emotional functioning is commonly assessed as the negative effects of illness such 
as depression, anxiety or worry. Cognitive functioning refers to memory or the 
ability to concentrate. Overall life satisfaction or QoL represents a person’s overall 
sense of well-being.     
The majority of HRQoL research has been conducted by interdisciplinary teams 
that follow the empiricist tradition of medicine. In this tradition, it is assumed that 
relevant psychological variables, which are pre-existent and distanced from the 
researcher, can be measured. This tradition leads to the theoretical framework of 
HRQoL’s multidimensional perspective that has formed the basis for development 
of the psychometric tools for measuring the HRQoL of individuals. Following this 
tradition the assumptions of the contents of good HRQoL are made a priori. The 
3constructs or domains of HRQoL are considered latent variables, which are elicited 
with separate items or questions. In multidimensional questionnaires these domains 
are not directly measurable.  If the questionnaire is well designed, each question 
should ideally be associated with one latent variable (Fayers & Hand, 2002). These 
questions typically ask for the frequency or intensity of different symptoms or 
feelings.  
Traditionally, most HRQoL research has been targeted toward solving practical 
problems, with investigators responding to specific research needs, such as 
providing tools for investigators to assess care outcomes beyond traditional 
morbidity and mortality (Wood-Dauphinee, 1999).  In light of all this, it is not 
surprising that a multidimensional evaluation of HRQoL is thought to be 
appropriate. In addition, it seems unnecessary to attribute a specific meaning to 
HRQoL outside the psychometric setting.  
It has been argued that there are several valid, reliable questionnaires available to 
measure a person’s health related QoL. There are two basic approaches to 
measurement of QoL; generic instruments that provide a summary health profile 
and disease specific instruments which focus on specific problems associated with a 
disease or area of functioning. The multidimensional construct of the definition 
helps to pinpoint the problem area.
The issues which are measured in HRQoL research are psychological and complex 
in nature; therefore, an empiricist approach and a naturalistic frame of reference 
may not fully capture the phenomenon.  HRQoL is a highly individual concept and 
it has also been argued that research-defined psychometric translations of HRQoL 
may not capture the subjective nature of an individual’s experience (Cox, 2004). 
Furthermore, these measures do not say anything about how these judgements of 
HRQoL are arrived at and how they are determined by expectations or experience 
(Carr, Gibson, & Robinson, 2001).  Nor do they indicate the person’s ability to 
adjust to the illness experience which could involve constantly changing  
expectations and insensitivity to changes during the course of the illness 
(Rosenberg, 1995). 
It has been argued that HRQoL concepts are not a part of comprehensive theories 
of human actions (Rosenberg, 1995).  In a recent  review article on theory-driven 
HRQoL models the, authors pointed out that only 15% of those QoL models were 
categorised as theoretical models (defined as a model that includes the structure of 
4elements and their relationship within a theory that explains these relationships) 
(Taillefer, Depuis, Roberg, & Le May, 2003) 
Some theorists have attempted to capture and describe HRQoL systematically. To 
give some examples, Sprangers, who introduced her model of response shift 
(Schwartz & Sprangers, 1999; Sprangers & Schwartz, 1999), and Leventhal’s self- 
regulation model of illness behaviour (Leventhal & Colman, 1997) have 
contributed to the field of HRQoL. According to Sparangers, the response shift  
refers to the changes in internal standards, in values, or in the conceptualisation of 
QoL, which are catalysed by health state changes (Schwartz et al., 1999).This 
model is an attempt to capture the adaptation process in which patients change their 
internal standards. There are several implications of defining the response shift 
(Schwartz et al., 1999). However, it is nearly impossible to quantify it, i.e., to 
decide which part of any observable change in HRQoL is due to a response shift.   
Leventhal and Colman (1997) suggest a process model, which asserts that 
judgments of quality of life reflect an individual's evaluation of the level of his or 
her functioning within a number of life domains, and the value or importance 
assigned to these domains. The authors propose that the judgment process involves 
a variety of heuristics or procedures that are affected by contextual factors. The 
framework suggests that an individual's common sense representations, affective 
reactions, procedures and actions designed to control the disease as well as 
contextual factors influence the patient’s judgements and behaviour. These factors 
affect salience, meaning and the importance of domains involved in HRQoL 
judgements (Leventhal et al., 1997). 
Sprangers et al (2002) have explained HRQoL with a crisis theory; i.e., a crisis 
occurs when the difficulty and importance of a problem are larger than the 
resources available to deal with it.   They found that the patients in crisis reported a 
poorer HRQoL and the patients post crisis reported a similar overall QoL and 
psychological distress as  healthy individuals (Sprangers, Tempelaar, van den 
Heuvel, & de Haes, 2002). However, patients post crisis experienced more physical 
distress and role activity impairment than healthy individuals. There were no 
significant or systematic differences between the mean levels of coping resources 
and strategies in the patients post crisis and healthy individuals. The patients in 
crisis were not able to make their coping resources and strategies more effective, 
whereas the patients post crisis seemed to have enhanced the effectiveness of self-
esteem in restoring their QoL compared to healthy people (Sprangers et al., 2002).  
5The notion of self-efficacy has been used as a theoretical framework for 
understanding the results of HRQoL studies.  (Self-efficacy refers to the belief that 
one is capable of performing the behaviour required to produce a desired outcome 
(Bandura, 1997)).  The concept of self-efficacy has been introduced in the self-
management of chronic illness and the discrepancy in chronically ill patients' 
perceptions of the importance and attainability of illness-related goals and their 
quality of life (Kuijer, 2003). Kuijer (2003) found that more discrepancy in goal 
importance and attainability was associated with lower levels of HRQoL.  
However, the association with physical well-being was only marginally significant. 
They suggest that the discrepancy measure reflects a psychological weighting of 
what is personally important and of what one is capable of doing, which  is more 
strongly related to psychological well-being than to physical well-being (Kuijer, 
2003).
Thus none of the theories related to HRQoL are psychological theories in the sense 
that they encompass the mechanisms of the human mind that specify all or the key 
issues studied under the umbrella of HRQoL. One psychological theory which 
could be adapted to HRQoL research is  a principle of psychic self-regulation 
according to which the individual attempts to function in ways that produce 
maximally/optimally articulated consequences for self-experience (Vuorinen, 
1986a, 1986b, 1986c).  Self-regulation covers all functions that exist to control 
actions and to modify mental processes to maintain psychic equilibrium. The goal 
of self-regulation is to keep the level of  psychic tension low or constant, because 
an  increase in the level of tension is experienced as distress and a decrease or 
stable level of tension is experienced  as pleasure or as having control over a 
situation (Vuorinen, 1986a).
This theory defines three types of levels of self-regulation: the most fundamental 
level is psychic work, which refers to the totality of those mental processes which 
an individual uses for achieving and  maintaining his psychic equilibrium. Psychic 
work consists of various mental operations: intentions, thoughts, affects, and 
motives. Another level of self-regulation is the psychosocial level, which refers to 
the need for other people. According to this theory, social relations are shaped to fit 
both internal goals and situational preconditions, therefore social interaction cannot 
be explained only by correlating personal and situational variables.   The 
psychophysical level, in turn, involves the use of the body with all its somatic 
processes for psychological purposes. This also applies when the environment or 
bodily functions limit a person’s external goals.  In these situations as well actions 
are reformed by how mental functions adjust to external constraints, i.e, how these 
constraints are related to self-experience. People are forced to maintain psychic 
 6 
equilibrium through psychic work.  Moreover, the meanings of other levels are 
conveyed through psychic work. The importance of psychic work means that 
external goals are secondary to internal goals, i.e., maintaining psychic equilibrium 
(Vuorinen, 1986a). This framework offers the systemic psychological explanation 
of how physical  and social factors are formed through psychic work, i.e., according 
to individuals’ own mental processes.   
 
HRQoL research is dominated by an empiricist psychometric tradition and the 
theoretical status of the HRQoL concept remains ambiguous (Rosenberg, 1995). 
Consequently, it has been argued that even though empirical research has provided 
valid and reliable data on the patients’ subjective perceptions of their HRQoL, it 
may preclude the need for especially qualitative approaches. The need has been 
shown for the added and independent value of an in depth analysis of experience 
and meaning of the disease and its treatment. Qualitative approaches in HRQoL 
research have potential for the introduction of new hypotheses, for providing 
powerful and detailed information about the personal experience, and for the 
validation of quantitative results (Strang, 2000). 
     
1.3   Breast cancer 
1.3.1 Epidemiology and risk factors 
Breast cancer is the most common cancer in women, and 210 631 cases were 
diagnosed in the EU in 1998 (http://www-dep.iarc.fr/eucan/eucan.htm,  
Last updated on 17/3/2003.). In Finland, 3 644  new breast cancer cases were 
diagnosed in the year 2001 (FinnishCancerRegistry, 2004). Breast cancer has many 
risk factors.  The risk of developing breast cancer increases with age (Annual, 
Databank, & Geneva, Last updated: November 2001). Early menarche, late 
menopause, nullipatrity or late age at first birth, obesity, alcohol use, family history 
of breast cancer and use of oestrogen and progestin postmenopausal hormone 
therapy for five years or more are known risk factors for breast cancer 
(Brekelmans, 2003; Kerlikowske et al., 2003; McTiernan, 2003). Population-based 
studies of the genetic epidemiology of female breast cancer have shown that only a 
small proportion of familial aspects of the disease can be explained by what is 
currently known about its causes. These include mutations in the genes BRCA1 and 
BRCA2, associated with a 10- to 20-fold increased risk of developing breast cancer 
(Hopper, 2001). The prognosis of breast cancer has greatly improved during recent 
decades and the five-year relative survival rate, based on Finnish cancer registry 
data, is nowadays 85%.  However, the prognosis varies widely between different 
7stages of breast cancer.  Despite the improved prognosis, breast cancer is the 
leading cause of cancer death in women (17% ) (Bray, Sankila, Ferlay, & Parkin, 
2002). Five-year relative survival rates vary from 93% for patients with localized 
disease to 69% with localised metastasis and 22% for distant metastasis (Teppo et 
al., 1999). The most common sites for metastasis are the skeleton, the lungs, the 
liver, the subcutaneous tissue of the skin and the lymphatic structures.  Advanced 
breast cancer is generally considered an incurable disease and therefore the benefits  
of therapy (survival and freedom from tumour-related symptoms) must be 
counterbalanced with treatment toxicity and the patients’ quality of life.  
1.3.2 Treatment of advanced breast cancer  
The first treatment of patients with advanced breast cancer, with no symptoms, who 
have hormone receptor positive tumours is usually hormonal therapy. When 
hormonal therapies are effective they are preferred, because they are less toxic than 
most chemotherapy regimens and have long-standing responses.  However, most 
patients with advanced breast cancer receive chemotherapy at some point during 
the illness.  Chemotherapy is indicated when the cancer is unresponsive to 
hormonal therapy or is rapidly progressive and life threatening.   Chemotherapy 
provides significant palliation and prolongation of survival in advanced breast 
cancer patients. The median survival time for metastatic breast cancer with 
conventional chemotherapy is 12-24 months (Bergh, Jonsson, Glimelius, & 
Nygren, 2001). As a first line chemotherapy for metastatic breast cancer, 
polychemotherapy results in a statistically significant survival gain compared with 
single agent therapy. Antracycline- containing combinations improve survival 
compared to non-antracycline combined chemotherapy, and higher doses are 
superior to lower doses (Bergh et al., 2001; Fossati et al., 1998). On the basis of  
these findings, the antracyclines (doxorubicin and epirubicin) are widely used as 
first line chemotherapy (Crown et al., 2002).  
Second line therapy for metastatic breast cancer refers to the treatment given to 
patients who had failed to respond to primary chemotherapy for advanced breast 
cancer. In the treatment of advanced breast cancer there are quite a few treatment 
opportunities available; however, the choice of second line treatment is determined
by the first line regimen used (Crown et al., 2002).  Response rates and survival 
gain for the second line of chemotherapy are lower compared to the first line 
therapy. The most active second line chemotherapy regimens are the taxanes 
(docetaxel and paclitaxel). The taxanes are relatively new treatments in breast 
cancer; in fact, the first study was reported in 1991 (Holmes et al., 1991).  The 
8clinical use of taxanes has now been widely evaluated, and taxanes are commonly 
considered to be the most effective second line therapy (Crown et al., 2002) with 
survival gain of up to 15 months (Nabholtz et al., 1999; Sjöström et al., 1999). The 
taxanes (docetaxel, paclitaxel) have also been proven to be of great therapeutic 
value in advanced breast cancer, yielding not only high response rates (Nabholtz et 
al., 1999)  but also prolongation of survival (Jassem et al., 2001; Nabholtz et al., 
1999). However, taxanes are considered to be relatively toxic treatments causing 
alopecia, asthenia, haematological and  neurological side-effects (Lister-Sharp, 
McDonagh, Khan, & Kleijnen, 2000).  Other treatments, including cyclophasmide, 
mitomycin c, viblastine, methotrexate, fluorouracil, and platinum compounds are 
considered to be alternatives to taxanes with antracycline resistant disease (Crown 
et al., 2002). 
1.4 Health related QoL in advanced breast cancer clinical trials 
The science of medical decision making has assumed that good choices are made 
on a rational basis, and in modern medicine the traditional endpoints of cancer 
treatment have been tumour response, disease free survival or survival. Until the 
mid 1980s, the length of survival time was the main measure for determining the 
value of chemotherapy for cancer (Gunnars, Nygren, & Glimelius, 2001). 
Increasingly, researchers have been faced with situations in which patients may not 
gain benefits from these traditional endpoints. Treatment should not exceed the 
positive effects, and small gains in terms of response and survival should be 
weighed against QoL. In palliative settings, chemotherapy has very limited efficacy 
in terms of traditional endpoints and therefore HRQoL should be an endpoint.   
Nowadays, there is greater understanding among researchers that the efficacy of 
therapeutic interventions should be evaluated by their impact on both the quantity 
and quality of life. 
The assessment of  HRQoL is an important endpoint in clinical trials with the aim 
of complementing the  traditional endpoints, i.e., tumour response, response time 
and survival time. Typically, there are three reasons why investigators are 
interested in HRQoL in cancer clinical trials: (1) as a means of assessing 
rehabilitation needs, (2) as an endpoint in evaluating treatment outcomes e.g., when 
comparing HRQoL against competing treatments and (3) as a predictor of the 
response to future treatment (Cella & Tulsky, 1993). HRQoL measurements are 
especially recommended: (1) in a trial in which no significant differences are 
expected in terms of cure, disease free survival or overall survival but one treatment 
is expected to be associated with more morbidity; (2) in a trial in which survival 
9and disease free survival or cure are expected to differ between treatment groups, 
but advantageous primary outcome is only achieved at the expense of major 
toxicity (Young et al., 1999). 
HRQoL should be the endpoint in advanced breast cancer clinical trials, because 
treatment is considered to be palliative, as the aim is not to cure and no significant 
differences are expected in somatic clinical endpoints. Even though it has been 
recognised that HRQoL is an important endpoint in advanced breast cancer, there 
have been only a few trials where HRQoL has been studied by using the EORTC 
QLQ-C30 (European Organization for Research and Treatment of Cancer Quality 
of Life core Questionnaire C30). 
Nabholtz and colleagues (2003) compared HRQoL in patients receiving docetaxel 
and doxorubicin or doxorubicin and cyclophosphamide as first line chemotherapy 
for metastatic breast cancer. They found no significant differences in global QoL 
between the treatment groups (Nabholtz et al., 2003). Kramer’s et al. (2000)  study 
was to compare the quality of life of patients treated with single-agent paclitaxel 
versus doxorubicin as first line chemotherapy for advanced breast cancer (Kramer, 
Curran, Piccart, de Haes, Bruning, Klijn, Bontenbal et al., 2000).   They found that 
doxorubicin was associated with significantly more nausea/vomiting (P=0.001), 
loss of appetite (P=0.010) and both treatments were associated with improved 
emotional function and reduction in psychological distress at cycle 3.  Norris and 
colleagues (2002) conducted a comparative study of vinorelbine combined with 
doxorubicin versus doxorubicin alone in disseminated metastatic or recurrent breast 
cancer. There were no significant differences in any HRQoL domains between the 
treatment groups of means scores over the first 6 cycles (Norris et al., 2000). 
However, QoL scores showed improvement over time in the global, emotional, 
social, pain and nausea/vomiting domains for patients receiving six cycles. The 
authors suggest that this might be the result of selection bias because only patients 
who were stable or responding to chemotherapy received six cycles (Norris et al., 
2000).
Jassem et al. (2001) compared the EORTC QLQ-C30 scores for patients receiving 
doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and 
cyclophosphamide (FAC) as first line therapy for women with metastatic breast 
cancer.  Significant differences were found in that physical functioning and pain, 
fatigue, insomnia and diarrhea favoured with FAC, whereas nausea/ vomiting 
favoured AT arm (Jassem et al., 2001).  Even third line chemotherapy may improve 
patients’ HRQoL.  In a study by Mc Lachlan et al. (1999), 34% of the patients in 
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third line theraphy achieved a clinically important change (i.e., more than 10 
points)  in global QoL  and 43% achieved a similar change in emotional 
functioning and 31 % in social functioning (McLachlan, Pintilie, & Tannock, 
1999). However, the level of compliance of this study was 94% at the start of 
chemotherapy and declined to 60%.  
Because the taxanes are relatively new treatments for advanced breast cancer and 
which are demonstrated to be effective, their impact on QoL has been only recently 
studied. There are only two HRQoL studies in which docetaxel has been compared 
to  another treatment (Chan et al., 1999; Nabholtz et al., 1999). Furthermore, one 
study compared the capecitabine plus docetaxel combination with docetaxel alone 
(O'Shaughnessy et al., 2002). In all of these studies HRQoL has been a secondary 
endpoint, while response rates and survival were the primary endpoints.   Chan’s 
(1999) phase III study compared docetaxel and doxorubicin in patients with 
metastatic breast cancer who had received previous alkylating agent-containing 
chemotherapy. HRQoL was measured by using the EORTC QLQ-C30. There were 
no differences in HRQoL scores between the treatment groups. Docetaxel produced 
a significantly higher rate of objective response than did doxorubicin (47.8% v 
33.3%; P =0.008 (Chan et al., 1999). The median time to disease progression was 
longer in the docetaxel group (26 weeks v 21 weeks; however, the difference was 
not significant). The median overall survival was similar for the two groups 
(docetaxel, 15 months; doxorubicin, 14 months). In  Nabholtz’s (1999)  study,  
docetaxel was compared with mitomycin plus vinblastine  in patients with 
metastatic breast cancer that was progressing despite previous anthracycline-
containing chemotherapy. The quality of life was measured by using the EORTC 
QLQ-C30; however, the analysis was limited to two key variables (global QoL and 
physical functioning). The results were again similar for both groups: there were no 
significant decreases in either group in physical functioning or global QoL from the 
baseline scores (Nabholtz et al., 1999).  The compliance of the study was similar 
for both treatment groups, but the attrition rate was higher in the mitomycin plus 
vinblastine group. This limits the interpretation of the results, and any conclusions 
should therefore be drawn with caution.  Docetaxel was significantly superior to 
mitomycin plus vinblastine in terms of response (30.0% v 11.6%; P < .0001), time 
to disease progression (19 v 1 weeks, P=.001, and survival (1.4 v 8.7 months, 
P=.0097).
A third clinical study by Sjöström et al. (1999)  comparared docetaxel to 
methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline 
failure. The clinical findings of the study were the following: there was a 
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significantly higher overall response rate for docetaxel, 42% (CR 8% + PR 34%), 
than for  the methotrexate and 5-fluorouracil group, 21% (CR 3% + PR 18%) (P < 
0.001). The median time to disease progression was 6.3 months for the docetaxel 
arm and 3.0 months for the methotrexate and 5-fluorouracil M-F arm (P < 0.001). 
Docetaxel also had a significantly higher response rate of 27% following the cross-
over compared to methotrexate and 5-fluorouracil (12%). The median overall 
survival, including the cross-over phase, was 10.4 months for the docetaxel and 
11.1 months for the methotrexate and 5-fluorouracil arm (P = 0.79). Significantly 
more side-effects (leucopenia, infections, neuropathy, oedema, asthenia, nail 
changes, alopecia) were seen in the docetaxel than in the methotrexate and 5-
fluorouracil group. However, grade 3 and 4 side effects were infrequent with both 
drugs, with the exception of fatigue, alopecia and infections (Sjöström et al, 1999).
In the context of this study, the HRQoL analysis was considered to be of such 
importance that it was published separately.  The results of this study will be 
examined more closely in the results section (STUDY I in this thesis). 
O'Shaughnessy et al.  (2002) compared capecitabine and docetaxel with single-
agent docetaxel in anthracycline-pretreated patients with advanced breast cancer. 
The EORTC QLQ-C30 global QoL scale was selected as a primary variable in 
assessing HRQoL. No significant differences were found over time. However, 
docetaxel and capecitabine resulted in significantly superior efficacy in time to 
disease progression (TTP) (median, 6.1 v 4.2 months ;P =.0001;), overall survival  
(median, 14.5 v 11.5 months; P =.0126), and objective tumour response rate (42% v 
30%, P =.006) compared with docetaxel (O'Shaughnessy et al., 2002). 
Gastrointestinal side effects and hand-foot syndrome were more common with the 
combination therapy, whereas myalgia, arthralgia, and neutropenic fever or sepsis 
were more common with docetaxel and capecitabine.  More grade 3 adverse events 
occurred with the combination therapy, whereas grade 4 events were slightly more 
common in docetaxel  with combination (O'Shaughnessy et al., 2002). It is, 
however, very difficult to conclude the impact of treatments on the patient’s global 
QoL, since the study population in the docetaxel group was only half the size of the 
study population in the  capecitabine and docetaxel group at week 30.   
Generally speaking, relatively few studies of HRQoL in advanced breast cancer 
have reported major differences between the treatment groups (Bottomley & 
Therasse, 2002). Furthermore,  HRQoL outcomes provided little information 
beyond those obtained from traditional medical outcomes, including toxicity or 
influenced clinical decision making (Goodwin, Black, Bordeleau, & Ganz, 2003). 
There might be several reasons: one reason for that might be that, for ethical 
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reasons, treatments compared in cancer clinical trials must be similar and there are 
no placebo controlled trials. Another reason is poor compliance or small sample 
sizes (Bottomley et al., 2002). In the studies where in which nonrandom missing 
data or selective attrition is evident, it is difficult to interpret the results. This means 
that patients who respond to the treatment response continue in the study, whereas 
the patients with disease progression drop out of the study. Therefore, any 
conclusions from longitudinal HRQoL data can be made from only a very short 
period of time after the baseline. This is the problem on two occasions in particular:  
(1) when the compliance is low, because as a result of serious treatment toxicity, 
progressive disease or death, data are more likely to be missing  (Fairclough, 
Peterson, & Chang, 1998) and (2) when the treatment’s efficacy clearly differs, 
because it is impossible to make any estimations of a patient’s HRQoL in whom the 
disease has progressed. These difficulties make the interpretation of the results 
difficult as well as decrease the significance of the power of HRQoL results as a 
basis of clinical decision making. 
1.5 The art of measuring HRQoL in cancer clinical trials  
The widest application of HRQoL measurements is their use in clinical randomised 
and descriptive trials. In these trials, the methodology for HRQoL should be as 
robust as the methodology for clinical outcomes. This requires a clear 
understanding of the reasons for the measurements, with a priori stated hypothesis 
and a study protocol in which the practical procedure of data collection and 
management are explained in detail in order to reduce error variance. In HRQoL 
methodology, it is essential to understand the possible sources of errors that are 
typical in measuring psychological aspects of human life. In this research field, 
however, the use of QoL measurements have been used to solve problems in the 
tradition of  medicine.  Many of the difficulties in using HRQoL questionnaires in 
the past have arisen from the poor design of the studies (Cull, 1997) and from poor 
compliance (Hurny et al., 1992). Recently, some systematic reviews on 
methodological issues in HRQoL in randomised trials have been published. The 
main limitations of the studies have been the following: very few, only about 6%, 
gave any definition of HRQoL, and only 13-40% of the studies stated a specific 
pre-trial HRQoL hypothesis (Bottomley, Vanvoorden, Flechtner, & Therasse, 
2003). Furthermore, quite common limitations were poor or not reported 
compliance, the lack of a clear approach to missing data and data analysis, the 
limited presentation of results and the lack of the use of clinical significance 
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(Bottomley, Efficace et al., 2003; Bottomley et al., 2002; Efficace et al., 2003; Lee 
& Chi, 2000).  
Despite the recognised weaknesses in HRQoL research, the U.S. Food and Drug 
Administration (FDA) recognises the benefits of HRQoL as a basis for the approval 
of new anticancer drugs. Therefore, many international research groups include 
HRQoL measurements in their studies. However, only about 10% of all randomised 
controlled cancer trials reported on quality of life (Sanders et al., 1998) and no 
FDA  approvals of oncology drugs between 1990-2002  were based on instruments 
measuring HRQoL (Johnson, Williams, & Pazdur, 2003). There are several 
possible reasons why introducing HRQoL into oncology has been difficult. Johnson 
et al. indicated that the main reasons the HRQoL assessments have not been well- 
conducted were unblinded assessments, large amounts of missing data, and poorly 
defined prospective analytic plans (Johnson et al., 2003). 
Not only has the field suffered from the methodological problems, but there are 
also barriers for physicians’ use of HRQoL information. Of physicians 84%,  felt 
that their knowledge of HRQoL literature is limited and relied primarily on clinical 
experience to assess HRQoL. In addition, they felt that QoL information was 
difficult to understand (Bezjak et al., 2001). It is also difficult to compare results 
across different studies especially as the studies use different, albeit well-known 
questionnaires such as the FACT-G (Functional Assessment Cancer Therapy) and 
the EORTC QLQ-C30.  When the pairs of corresponding subscales of the EORTC 
QLQ- C30 and the FACT-G were compared, only low to moderate correlations 
were found and discrepancies between the instruments resulted in contradictory 
conclusions (Holzner et al., 2001). 
With the increasing number of studies on HRQoL issues, researchers in the field 
have faced various challenges associated with methods, concepts, practical 
applications, and clinicians’ attitudes towards HRQoL. However, there has been 
progress and some methodological problems are slowly being overcome. One 
reason might be that an increasing amount of literature is devoted to providing 
guidelines for how to design, organise, analyse and interpret HRQoL in clinical 
trials. In these guidelines, the following aspects are covered: the rationale of 
HRQoL measurements as a primary or secondary endpoint and the selection of the 
appropriate instrument (usually validated instruments the European Organization 
for Research and Treatment of Cancer (EORTC) and Functional Assessment of 
Cancer Therapy-General (FACT-G) instruments are recommended). There are 
instructions on the number of measurement points  (at least three points of 
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measurement before, during and after treatment),  on practical procedures for data 
collection and  on how to inform patients and the staff; advice for monitoring 
compliance; recommendations for enhancing compliance and instructions for data 
management. There are recommendations for sample sizes, handling and reporting 
missing data, data analysis, the interpretation of data and clinical significance,and 
reporting results (Brandberg, 2000; Fayers & Bottomley, 2002; Fayers et al., 1997; 
Osoba, 1998; Staquet, Hays, & Fayers, 1998; Velikova, Stark, & Selby, 1999; 
Young et al., 1999). 
Even though guidelines are available, there have been problems in reporting the 
results of those studies. The standards that are lacking on how to report HRQoL 
studies has made it difficult to interpret individual studies and to conduct 
systematic reviews (Lee et al., 2000). Only recently have suggestions been made 
for a minimum set of criteria for assessing reported outcomes in cancer clinical 
trials (Efficace et al., 2003). Since 1998 there have been guidelines on interpreting 
clinical significance and reference values for diverse cancer populations available 
for the EORTC QLQ-C30 (Fayers, Weeden, & Curran, 1998; Osoba et al., 1998) 
but only few researchers have used them. These aid in the meaningful 
interpretation of results and are useful for comparison with a group of patients with 
similar characteristics.  .  
The present study protocol was written in 1994. At that time, despite the growing 
interest in measuring HRQoL, only broad instructions on how to measure and the 
reasons for measuring HRQoL  were available (Aaronson, 1992; Cella et al., 1990; 
Donovan, Sanson-Fisher, & Redman, 1989; Kaasa, 1992; Maguire & Selby, 1989). 
In the literature, critical reflection on practical and methodological issues was 
lacking.  
In the guidelines for how to design and report HRQoL within  EORTC trials, it is 
stated that in many centres there are no data managers or study nurses helping the 
clinicians to collect the HRQoL data (Kiebert, Curran, & Aaronson, 1998). In 
another set of guidelines it is noted that clinicians may or may not collect the 
HRQoL data.  Although, in general, it is recommended that a person other than the  
physician in charge, administers the questionnaire, because it has been suggested 
that patients try to please their doctor and thus the responses may be distorted if the 
person responsible for managing the treatment is present while the patients 
complete the forms (Fayers et al., 1997). These are implicit statements of optional 
confidentiality in HRQoL measurements. In the guidelines this source of error can 
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be due to the vagueness of the data collection procedure and lack of confidentiality 
is not recognized. 
The issue of confidentiality should be especially stressed in randomised clinical 
trials, in which a new treatment regimen is compared with the usual treatment. 
After randomisation, patients usually know which treatment is the new one and 
therefore that kind of research frame is evocative of expectations of treatment 
efficacy. This is especially important in palliative settings where hope for better 
HRQoL rather than for excessive survival gain should be given. There is some 
evidence of how small a chance of gain from a treatment the patients are willing to 
accept.  According to a classic  study by Slevin (1990), most patients were willing 
to accept intensive chemotherapy for a very small chance of benefit; i.e., for a 1% 
chance of a cure, and when asked about the relief of symptoms, 43% of patients 
accepted intensive treatment when the chance of relief was very small (Slevin et al., 
1990). Even in a palliative setting, 78% of patients favoured chemotherapy to the 
best supportive care, and patients who were striving more for the length of life than 
HRQoL had strong preferences for palliative chemotherapy (Koedoot et al., 2003).  
Jansen et al. (2001) found that 40 % of breast cancer patients receiving adjuvant 
chemotherapy were willing to accept therapy even if it had no clinical benefit at all, 
with zero gain in survival (Jansen et al., 2001). This study may not be applicable as 
such in palliative settings, however, as it seems that treatment has a dual function 
for patients: to gain a chance for survival and to allay anxiety. This is because as 
long as thetreatment lasts and new treatments can be proposed, even though there 
my be only very little or not efficacious at all in terms of survival, fears may be 
controlled when a treatment offers some possible benefit and hope (de Haes & 
Koedoot, 2003; Slevin et al., 1990).
These results lend weight to our argument that it is essential that HRQoL 
measurements are strictly confidential in regard to those in charge of treatment, in 
order to avoid the bias that might occur if patients try to please the physician in 
order to continue the treatment. Even in the most recent EORTC guidelines there is 
only a recommendation that the questionnaires completed by the patients are not to 
be shown to their physician or other personnel responsible for their treatment 
(Young et al., 1999). In the light of all this, it seems that is not fully recognised how 
the lack of the confidentiality of the answers can jeopardise the validity of the 
results.  
The exactness of the timing of HRQoL administration has not been focussed on 
earlier literature. However, due to the cyclic nature of the treatments, this should be 
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an important issue to control in order to enhance the reliability of the study. In the 
EORTC guidelines the instructions for the timing of measurements are to be time-
based or event-based (Young et al., 1999). Time-based measurements give a set 
number of days or weeks after randomisation independent of the treatment 
schedule. In an event-based approach, the measurements are to be given to coincide 
with specific treatment cycles. It is recommended that assessments are usually 
scheduled to take place immediately before treatment and the acceptable time 
windows should be specified beforehand – during the treatment the windows 
should be narrow (e.g +/- week) (Young et al., 1999).  Hence, the recommendations 
for the exactness of timing are vague. 
Thus, although some studies indirectly or directly have touched upon the issue of 
the timing of HRQoL questionnaires, little attention has been paid to how exact the 
timing of the HRQoL assessments should be.  A classic validation study of the 
LASA (linear analog self-assessment technique) was the first study to raise the 
issue of  timing.  The authors suggested that there were substantial differences in 
patients’ HRQoL if the  measurements were done on the day that the treatment was 
given or 3 days later (Priestman & Baum, 1976). In a study designed to test the 
responsiveness of the EORTC QLQ-C30, Osoba and colleagues (1994) showed that 
decreases were seen in physical, role and social functioning and in the global 
quality of life eight days after chemotherapy compared to the baseline scores.  In 
addition, there was greater fatigue, nausea and vomiting compared to before the 
chemotherapy (Osoba et al., 1994). Hurny and colleagues (1994) studied the timing 
of baseline assessment in an adjuvant trial and noted that the timing of assessment 
in relation to chemotherapy especially affects measures sensitive to toxicity. 
According to him, the effect of timing was on the same order of magnitude as the 
effect of treatment (Hurny et al., 1994).  Pater et al. (1998) conducted a study 
altering the time of administration and the time frame of quality of life assessments 
in clinical trials. Patients who completed questionnaires on day 8 were more likely 
to report deterioration in the quality of life if their questionnaire had a 7-day time 
frame rather than a 3-day time frame (Pater J et al., 1998). A clinical model of  
HRQoL assessments for cancer patients suggested by Klee et al. showed that results 
from patients who did not complete the questionnaire within the specified time 
windows tended to dilute the findings from the group who did  (Klee, King, 
Machin, & Hansen, 2000). In conclusion, there are some studies that directly or 
indirectly show the effect of the timing of HRQoL questionnaires.   
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1.6  Physical functioning, toxicity and HRQoL  
It is widely agreed that HRQoL cannot be reduced to physical functioning or 
treatment toxicity, even though these are assumed to be important determinants. In 
cancer clinical trials, physical performance is commonly assessed using the 
Karnofsky Performance Status (KPS) or WHO performance status scales. The KPS 
scale ranks performance status ordinally from 100 (asymptomatic, normal function) 
to 0 (death). The WHO performance status ranks performance from 4 (normal 
functioning) to 0 (death). When using these scales the patient’s physical 
functioning is assessed by the physician, usually by asking the patient.  These 
measures are widely used and commonly accepted both in clinical practice and in 
research settings.   
If physical functioning is, however, one of the most important determinants of 
HRQoL, then the two should be highly interconnected. Therefore, in processes of 
validating HRQoL instruments, in the scoring of physical functioning either the 
WHO performance or the Karnofsky performance score has traditionally been used 
as an anchor variable. In research, the validity of the EORTC QLQ-C30, in terms of 
the ability of the scales to distinguish between subgroups of patients on the basis of 
clinical status (i.e., known group comparisons) has been proved by using patients 
with different performance statuses.  There is a strong linkage between WHO or 
Karnofsky performance status scores and several domains of the EORTC QLQ-
C30; these are all in the expected direction (Aaronson et al., 1993; Kobayashi et al., 
1998; Kyriaki et al., 2001; McLachlan, Devins, & Goodwin, 1998; Osoba et al., 
1994; Schaafsma & Osoba, 1994). The strongest correlations were found between 
the WHO performance score and  role and social functioning as well as global QoL 
(Schaafsma et al., 1994). Significant differences between the groups with different 
KPS statuses or different performance scores have been documented (Bjordal et al., 
2000; Kyriaki et al., 2001). Patients with poorer performance scores reported 
significantly poorer QoL in all subscales  measured with the EORTC QLQ-C30 
(Aaronson et al., 1993; Bjordal et al., 2000; Kobayashi et al., 1998) with the 
exception of emotional and social functioning in Aaronson’s  (1993) study. 
In cancer clinical trials the physician assesses the treatment toxicity most often by 
using the standardised WHO criteria (Miller, Hoogstraten, Staquet, & Winklaer, 
1981). In connection with clinical trials, the HRQoL results and the clinical results 
are often reported and analysed separately, and therefore the relationship between 
the treatment toxicity and HRQoL often remains unclear. However, a study by 
Macquart-Moulin (2000) found that the EORTC QLQ-C30 global score was 
significantly correlated with the total number of the chemotherapy treatment’s side- 
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effects (correlation coefficient r = 0.41; p< 0.001)  (Macquart-Moulin et al., 
2000).Pain, fatigue and sleep disturbance has also been found to correlate 
significantly to the global QoL scale (McLachlan et al., 1998). 
 
Physicians make their clinical decisions by assessing the treatment efficacy, 
physical functioning and bearable side-effects. These assessments naturally depend 
on various uncontrollable variables, such as the nature of the communication 
between the patient and the physician, the personality of the physician and the 
patient, etc.  However, there has been some evidence that there is a discrepancy 
between the physician- assessed toxicity and the patient-assessed toxicity. A study 
by Sigurdardottir (1996) compared the physician-rated clinical outcome and patient 
reports, and found no correlation between them, with the exception of neurotoxicity 
(Sigurdardottir, Bolund, & Sullivan, 1996).  A study by Stromgren and colleagues 
(2001) investigated  the extent to which the symptoms experienced by advanced 
cancer patients were covered by the medical records. The analysis revealed good 
concordance for pain, but most other symptoms or problems (i.e. nausea / vomiting, 
reduced appetite,  dyspnoea and fatigue)  were reported much more often by 
patients than by their doctors (Stromgren et al., 2001). The data collection in cancer 
clinical trials using clinical research forms (CRF) is a more structured system of 
collecting information than medical records.  Clinical research forms are planned to 
cover predetermined variables, using a well-known rating system (such as one 
according to WHO).  In a study by Geels et al. (2000) comparing the amount of 
symptoms recorded in clinical research forms and patient-assessed HRQoL 
questionnaires, they found that the most commonly reported baseline symptoms 
were cancer pain in 38% (CRF data) and 81% of patients (QoL data) and tiredness 
in 26% (CRF data) and 89% (QoL data) of patients (Geels et al., 2000). Hence, of 
any given symptom, the QoL questionnaires identified  a much higher number of 
patients with that symptom. In a recent study by Brandberg  and colleagues, 
correlations between toxicity registration and the HRQoL questionnaire collected 
data showed only weak correlations (Brandberg et al., 2003). However, the ratings 
of any single toxicity assessed  by the patient and the doctor were not reported in 
any of these studies. 
 
When using the same assessment method  i.e., the EORTC QLQ-30,   there was 
reasonable agreement in the mean scores between patients, and physicians, for 
many domains of HRQoL (Wilson, Dowling, Abdolell, & Tannock, 2000) . 
However, there was substantial discordance between scores when considering 
individual patients. For patients with metastatic breast cancer, physicians 
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systematically underestimated overall QoL, social functioning, role functioning and 
diarrhoea (Wilson et al., 2000).  
It is therefore theoretically and practically important to understand the relationship 
between the structured physician-assessed toxicity and physical functioning 
parameters and the structured reports by patients of their HRQoL.    
 
.  
1.7  The prognostic value of HRQoL scores for cancer 
According to Cella (1993), one of the main reasons to conduct HRQoL research 
alongside a clinical trial is to provide a predictor of response to future treatment. It 
is a popular belief that psychosocial factors, including HRQoL, can influence 
survival from cancer. However, there is little consistent evidence of important 
psychosocial factors on survival (Petticrew, Bell, & Hunter, 2002). Several studies 
have shown that HRQoL data may predict cancer patients’ survival. The most 
convincing evidence for a cause-and-effect relationship between HRQoL 
parameters and the outcome of a malignant disease comes from randomised 
controlled clinical trials for which other related factors relevant to outcome, such as 
treatment and the characteristics of the tumour are controlled.  The purpose of 
studying prognostic factors is to assist clinicians in decision making concerning 
treatment choices and rehabilitation.  The majority of studies examining the 
association between survival and HRQoL data show a relationship between the 
HRQoL scores and survival (Blazeby, Brookes, & Alderson, 2001; Coates et al., 
2000; Coates, Porzsolt, & Osoba, 1997; Dancey et al., 1997; Jerkeman et al., 2001; 
Maisey et al., 2002; Montazeri et al., 2001; Seidman et al., 1995; Tamburini, 
Brunelli, Rosso, & Ventafridda, 1996; Wisloff & Hjorth, 1997). 
 
Only a handful of studies with a sufficient study population examine the prognostic 
value of the HRQoL score measured using the EORTC QLQ-C30. There are two 
large studies with heterogenic cancer populations (including breast cancer patients) 
receiving different types of chemotherapy. In Coates’ and colleagues (1997)  study, 
the global scale and the scales of physical, role, emotional, cognitive and social 
function were each significantly predictive of subsequent survival duration in the 
univariate analysis. In the multivariate analysis, physical, social and global scales 
provided independent prognostic data (Coates et al., 1997). In Dancey’s study, the 
univariate analysis showed that  physical, role , social functioning, global  QoL and 
symptoms of fatigue, pain, dyspnoea, appetite loss and constipation were predictive 
of survival. Surprisingly, according to the multivariate analysis, the HRQoL 
variables associated with prolonged survival were the absence of dyspnoea, a high 
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global QoL and low emotional functioning (Dancey et al., 1997). In addition, they 
found that the emotional functioning score was not associated with survival with 
those patients who had high global QoL scores. These somewhat ambiguous results 
may have raised the question of the prognostic value of HRQoL data in controlled 
cancer clinical trials with a very specific study population. 
There are two studies by Coates and colleagues exploring  the prognostic value of 
HRQoL scores in breast cancer patients using LASA (linear analog self-
assessment) and the QLI (quality of life index) (Coates et al., 1992; Coates et al., 
2000). In a classic study by Coates, the patient LASA scores for physical well-
being, mood, nausea and vomiting, appetite, and overall QoL (but not pain) at the 
commencement of treatment were significant predictors of subsequent survival. In 
addition, they found that both the QLI and physical well-being were prognostically 
independent of tumour response (Coates et al., 1992) Another interesting and large 
study by Coates et al. (2000),  in which they compared the prognostic value of 
HRQoL scores in the adjuvant setting and after relapse in two randomised trials in 
more than 2000 breast cancer patients. Their results showed that any prognostic 
significance of HRQoL scores in the adjuvant setting is minimal or obscured by 
chemotherapy effects, but there is a strong prognostic significance of HRQoL 
scores after disease relapse (Coates et al., 2000). This result increases the 
ambivalence towards the prognostic value of HRQoL data. 
There has been some evidence that change scores from baseline HRQoL can 
predict overall survival. In Blazeby’s study, improvements in emotional functioning 
were significantly associated with longer survival in 38 patients (Blazeby et al., 
2001). In another study with 64 advanced breast cancer patients, change scores in 
physical well-being, mood, pain, and overall QoL were predictive for longer overall 
survival (Coates et al., 1992). 
When compared to the extent of use EORTC QLQ-C30 in cancer clinical trials 
(over 3000 studies worldwide), surprisingly few reports have focussed on the 
HRQoL score’s value for prognostic survival or treatment response  (Coates et al., 
2000; Jerkeman et al., 2001; Kramer, Curran, Piccart, de Haes, Bruning, Klijn, Van 
Hoorebeeck et al., 2000; Maisey et al., 2002; Norris et al., 2000; Roychowdhury, 
Hayden, & Liepa, 2003; Wisloff et al., 1997). The results of even those few studies 
show somewhat confusing results. In the studies using a univariate analysis, all 
other domains than the financial domain EORTC QLQ-C30 scales have been 
identified as significant independent predictors of survival. However, which 
combinations of the EORTC QLQ-C30 domains  have had predictive value varies 
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from study to study. According to the results based on multivariate analysis, only 
physical functioning (Wisloff et al., 1997) global QoL (Jerkeman et al., 2001; 
Maisey et al., 2002; Montazeri et al., 2001; Norris et al., 2000), dyspnoea, fatigue 
and emotional functioning have been identified to be prognostic for survival  
(Kramer, Curran, Piccart, de Haes, Bruning, Klijn, Van Hoorebeeck et al., 2000).  
In Roychowdhury et. al’s (2003) study high physical functioning and low role 
functioning and the absence of appetite loss were predictive for longer survival.  
Most studies have reported that HRQoL is only significant for overall survival, 
although two studies have included the response to treatment as an outcome 
(Kramer, Curran, Piccart, de Haes, Bruning, Klijn, Van Hoorebeeck et al., 2000; 
Roychowdhury et al., 2003). In the univariate analysis, global QoL, physical, 
social, emotional functioning, pain, fatigue and anorexia  were significant 
predictors for time to progression of the disease and time to treatment failure;  in 
addition, role functioning and insomnia were predictors for progression of the 
disease, and dyspnoea for time to treatment failure (Roychowdhury et al., 2003). In 
the multivariate model, positive prognostic factors for time to  the progression of 
the disease were good performance status and minimal fatigue; for time to 
treatment failure, they were minimal fatigue and no anorexia. Global QoL was a 
significant predictor of outcome in the univariate analysis but was not retained in 
the multivariate model (Roychowdhury et al., 2003).  In  Kramer’s (2000) study for 
treatment response, dyspnoea, fatigue and global QoL were significant predictive 
factors in the univariate analysis. The final multivariate model for response to 
treatment selected dyspnoea (P=<0.001) using forward selection, but model 
instability was indicated by the inclusion of fatigue and emotional function in the 
final model when backward selection was used (Kramer, Curran, Piccart, de Haes, 
Bruning, Klijn, Van Hoorebeeck et al., 2000).  
Thus, it can be argued that some HRQoL parameters seem to have independent 
prognostic value for treatment response; their prognostic importance needs further 
evaluation. The evidence linking HRQoL and survival is somewhat incoherent and 
some of these studies suffer from methodological problems. There are limitations in 
the study population (heterogeneity connected with   cancer types and stages, the 
size of the study population), the various differing questionnaires used and 
problems of compliance. The very limited number of studies and inconstant results 
raise the question of publishing bias towards negative results. In the light of all this, 
it is very difficult to make conclusions about the prognostic value of HRQoL. 
Therefore, further work is required to confirm the prognostic value of  HRQoL. To 
our knowledge, there were no earlier studies of the prognostic value of EORTC 
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QLQ- C30 scores for both survival and  the time to disease progression in patients 
receiving second line chemotherapy for advanced cancer.  
1.8  Qualitative approaches assessing cancer patients HRQoL 
Using questionnaires as research methods for HRQoL issues represents a 
compromise between the desire for quick, practical, easily understood simple 
questions and, on the other hand, our recognition that such a simple method never 
gives us in depth understanding of the unique situation of individual. In the field of 
HRQoL research, there is a polarisation of qualitative versus quantitative 
approaches, as well as a mutual misunderstanding of the complementary potential 
of such different approaches. There is an epistemological difference between the 
qualitative and quantitative approaches to the study of HRQoL. Qualitative 
approaches such as phenomenology focus entirely on subjective meanings of 
health-related experiences, and the analyses of these are not primarily for the sake 
of comparison.
When using quality of life instruments, one presumes that the point of reference 
does not move, i.e. that individual attitudes towards a particular construct remain 
stable (Breetvelt & Van Dam, 1991). Thus, it has been argued that cognitive states 
are important for Quality of Life, because the intensity with which the patient 
suffers from her physical state often depends on the way these are cognitively or 
emotionally interpreted, e.g., as indicators of remission or progression or as side-
effects of a successful or of an unsuccessful treatment (Birnbacher, 1999). This 
kind of personal meaning is always underlying the experience of QoL. According 
to the theory of the principle of psychic self-regulation, a person uses psychic work 
i.e. mental processes (intentions, thoughts, affects, motives) for achieving and for 
maintaining her psychic equilibrium (Vuorinen, 1986a, 1986b, 1986c).  In the light 
of this systemic approach, it is no wonder that correlative theories of QoL cannot 
capture the phenomenon called HRQoL, and therefore qualitative approaches are 
needed to complement the HRQoL research.  It is encouraging that there is so much 
knowledge about the basic patterns of patients’ HRQoL, and to some extent, even 
knowledge of more subjective views of cancer patients’ experiences. One of the 
greatest challenges of future research is how to integrate both kinds of information 
in a meaningful way.  
So far there have been only a handful of researchers, most typically in the field of 
nursing science,  who have adopted a qualitative approach in assessing the HRQoL 
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of patients with cancer.  Because there are only few qualitative studies exploring 
the subjective meanings for breast cancer patients and the nature of the findings is 
descriptive, other studies than those on breast cancer will also be discussed in this 
section.
A classic interview study of breast cancer patients’ adjustment to threatening events 
is not precisely a study of HRQoL as such; however, it cannot be ignored, because 
it has systematically documented the means of adjustment to breast cancer.   
Taylor’s (1983) theory of cognitive adaptation to illness suggests that coping with 
breast cancer consists of three processes: (1) a search for meaning (e.g., patients’ 
attempts to understand why they developed cancer,  (2) a search for mastery (the 
belief that they can control the course of illness, and (3) self-enhancement (social 
comparison, whereby women analyse their condition in terms of others they know). 
These cognitive restructurings are in large part based on illusion (defined as a 
perception that represents what is perceived in a different way than it is in reality), 
i.e., unrealistically positive self-evaluation, exaggerated perceptions of control or 
unrealistic optimism (Taylor, 1983; Taylor & Brown, 1999). These illusions appear 
to foster traditional criteria of mental health, including the ability to be happy, and 
to help people to profit from negative life events that are unavoidable by enabling 
them to put those events in the best light  (Taylor, 1983; Taylor et al., 1999).  
Lam & Fielding (2003) conducted a phenomenological study of 17 Chinese women 
with breast cancer. Patients were interviewed on the completion of their initial 
treatment.  In this study the treatments and stages of the disease varied widely 
(tumour stage from III to I, the treatments were chemotherapy, radiation or 
hormonal therapy or a combination). Thematic analysis suggested that the 
identification and treatment of the disease included the difficulty of living in 
uncertainty and of maintaining and regaining normalcy in a superstitious society. 
The initial uncertainty of disease detection and the diagnostic process were 
characterised by shock and disbelief mingled with a fear of death. The thematic 
analysis of that study suggested that breast cancer not only disrupts the fabric of 
daily life but changes in appearance proved to be problematic for those women who 
tried to hide their disease to protect themselves against stigmatisation and social 
exclusion. (Lam & Fielding, 2003).  
Another qualitative study of breast cancer patients focussed on the existential issues 
of 10 newly diagnosed breast cancer patients. Again there were broad variations in 
the sense of disease development and the type of cancer treatment (Landmark, 
Strandmark, & Wahl, 2001). They found that the existential aspects connected with 
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the core category, the will to live, were a central issue in recovery and survival. The 
patients’ energy was all channelled into the fight for life. This included different 
levels of life expectations, the fight against death, life related to the future, religious 
beliefs and doubts and increased awareness of the values of life. However, these 
meanings may not be adapted as such to patients with advanced breast cancer, even 
though adherence to treatment can be seen as a manifest of the will to live.    
Nelson (1996) explored the experiences of uncertainty of 9 women with breast 
cancer. Living with the vicissitude or irregularity of emotions was found to be a 
powerful aspect of uncertainty. The presence of support during uncertainty 
influenced the patients’ perceptions and interpretations. Relying on support through 
relationships included a sense of optimism and hope from others. Uncertainty 
challenged the patients to learn new ways of being in the world and although breast 
cancer was a negative life experience, the women began to focus on the positive 
aspects of life, which made them more aware of what was important in their lives.  
Moreover, the reflection of self in the world had a powerful effect on the patients’ 
uncertainty experiences. To deal with uncertainty, the patients had to understand 
their disease and put it into a broader and meaningful life perspective (Nelson, 
1996).
A consecutive series of qualitative research on  breast cancer patients at different 
stages of the disease and receiving  different treatments was performed by Arman 
(Arman & Rehnsfeldt, 2002; Arman, Rehnsfeldt, Carlsson, & Hamrin, 2001; 
Arman, Rehnsfeldt, Lindholm, & Hamrin, 2002). The studies focussed on 
experiences of life changes, the search for meaning , and suffering. In her first 
study, she used qualitative content analysis in order to understand the reported 
changes of life perspective in interviews with 59 women (Arman et al., 2001). The 
women experienced both beneficial and harmful changes in life perspective.  The 
findings of that study indicated that these women's views of their relationships with 
others grew more valuable, and their relationships with husbands were described as 
improved. Their self-confidence and experience of strength improved, and they 
regarded life as being more enriched. The disease made them look more positively 
at life and gave life a deeper value.  The women experienced a change in their 
disposition towards becoming more fragile and low-spirited as a hardship. They 
described the aetiology of the disease from several interacting perspectives that also 
affected their ideas of how to achieve well-being and health. Often mentioned were 
the emotional conditions (grief or stress) they had experienced during their life.  
Arman’s second study was a qualitative case study (four women were interviewed 
four times) focussing particularly on changes in life perspective and on obtaining a 
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deeper and more profound understanding of the lives of women living with breast 
cancer (Arman & Rehnsfeldt, 2002). The women experienced an increased 
awareness of the relationship between life and death, which constituted a disclosure 
rather than an actual change in life perspective, and often underwent an increase in 
the desire to live their lives in accordance with their own values. This revitalised 
view of life increased the desire for taking control of one’s life and daring to be 
oneself.  However, when it proved impossible to live in accordance with their new 
insights, the women were particularly frustrated (Arman & Rehnsfeldt, 2002).  
The challenges for women with ovarian and for advanced breast cancer are similar 
both physically and psychologically because of the advanced nature of the disease, 
the side effects of the chemotherapy treatments, the repetitive cycles of aggressive 
therapy, and the perceived loss of femininity. Therefore, results of the qualitative 
studies of one cancer might be applicable to the other. Howell and colleagues have 
conducted qualitative studies of 18 patients with ovarian cancer (Howell, Fitch, & 
Deane, 2003a, 2003b). The women reported the myriad day-to-day changes in their 
lives including the inability to continue employment, feeling different about 
themselves, altered relationships with friends, the impact on the family, changing 
roles and fears for husbands, altered sexuality and worries about children (Howell 
et al., 2003a).   The major challenges they had to face were living with uncertainty, 
lack of control, the fear of the unknown and the stigma of cancer and facing death.  
The women described many sources of support (including family members, friends, 
andchurch community) that helped them to get through the experience of living 
with ovarian cancer. (Howell et al., 2003a). Howell conducted  another study to 
describe  ovarian cancer patients’ experiences confronting disease recurrence 
(Howell et al., 2003b). Treatment for recurrent ovarian cancer is always palliative. 
Four primary themes emerged from the analysis of the interview transcripts: (1) 
waiting for recurrence was described as frightening, (2) facing the diagnosis of 
recurrence, (3) managing treatment-related concerns in that patients felt that there 
were few treatment options available, and for patients who had had difficult 
complications with the earlier treatment, facing the treatment again was described 
as particularly challenging, and  (4) attempting to regain control by engaging in 
unproven alternative therapies. Those women (12 of 18) who used alternative 
therapies felt that alternative therapies helped them feel that they had a sense of 
control over their disease.  
There are three qualitative studies exploring the meanings of suffering in persons 
living with cancer (Arman & Rehnsfeldt, 2003; Kuuppelomäki, 1998; Ohlen, 
Bengtsson, Skott, & Segesten, 2002). Kuuppelomäki (1998) identified three 
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different dimensions in patients’ experiences of suffering, i.e. the physical, 
psychological and social, in a study of 32 patients with incurable cancer. Physical 
suffering was divided into two categories: caused by illness itself such as fatigue 
and pain or treatment- related suffering i.e. the side- effects of chemotherapy. 
Psychological suffering was most typically manifested in depression. Social 
suffering was expressed when the general deterioration and the fear of infection 
caused them to withdraw into their home or hospital. Ohlen and colleagues (2002)  
explored the meanings of alleviated suffering in persons living with life-threatening 
cancer.   In that phenomenological study, 16 patients with cancer who were 
receiving palliative treatment were interviewed. The meanings that were related to 
the alleviation of suffering were (1) having endurable bodily experiences; (2) being 
independent and feeling at home; (3) having feelings of connectedness with other 
people; (3) taking a long term view of the suffering as pleasure and joy give the  
strength and courage to face the suffering again; (4) being lifted out of the 
suffering,  meaning that joy and pleasure arise from the bottom of the soul and 
make the person less vulnerable to suffering , and  (5) having an inner peace. As an 
interpreted whole, the alleviation of suffering was found to be an embodied 
experience of "being in a lived retreat." This means that a person with life- 
threatening cancer experiences time and space as being herself, on her own 
conditions and in ways that alleviate suffering (Ohlen et al., 2002).  This lived 
retreat can provide a feeling of being at home in an existential sense, creating 
peace, rest, confidence, and breathing space in the person's suffering. It means 
coping with an altered body and feeling dignified (Ohlen et al., 2002).  
In Arman’s third study, she focussed on the suffering experiences of a sample of 17 
women (Arman, Rehnsfeldt et al., 2002). The findings elucidate how the suffering 
experience touched the women's inner existence and values. According to Arman, 
suffering can metaphorically be described as a "field of forces", which contains the 
movement of changes, adjustment, emptiness but also growth, insight and power, 
that affected everything in the women's lives, including their views of themselves 
and their relationships. Existential questions were raised about life, death, and the 
meaning of life. The suffering was encompassed by questions of why, causal 
explanations and the search for meaning. In their suffering, the women's 
dependency upon significant others, as well as healthcare personnel, was 
prominent. Suffering seemed to be expressed, increased, created, and alleviated in 
the relationship to the other person, and increased when the person was denied the 
possibility to be authentic in his or her relationships (Arman, Rehnsfeldt et al., 
2002).
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Very few qualitative studies focus on the meaning of chemotherapy.  In a classic 
study by Nerenz  et al. (1982) based on a structured interview of 61 patients 
receiving chemotherapy, it was found that vague, diffuse side effects such as 
tiredness and pain were more likely to be associated with distress than were acute, 
specific side effects such as nausea and vomiting (Nerenz, Leventhal, & Love, 
1982). Another study focussed on the meanings assigned to the experience of 
receiving chemotherapy among women recently diagnosed with breast cancer 
(Richer & Ezer, 2002). The findings were based on 56 interviews of ten women, 
with different kinds of chemotherapy treatments for different stages of breast 
cancer.  Women described three dimensions of their experience with breast cancer 
and chemotherapy: 1) "living in it" represents an interpersonal dimension that 
includes cognitive and emotional processing of the experience of having cancer and 
receiving chemotherapy,   2) "living with it" represents an interpersonal dimension 
which included sparing the family, unwanted sympathies and life around the clinic, 
and  3) "moving on" represents the phase when women started to face their future, 
by seeking a  new balance and making plans for the future.  All these experiences 
occurred with both existential and situational meanings.  The existential meaning 
seemed to be present in varying degrees of intensity throughout the treatment, 
whereas the situational meanings were predominant at the beginning of the 
treatment phase and became less important as the treatment progressed (Richer et 
al., 2002). 
Common themes, which emerge from qualitative studies of cancer patients’ 
experiences: namely the uncertainty, changed attitudes, the life search for meaning, 
attempts to regain control, the importance of relationships and altered lifestyles. 
Although most of the qualitative studies of breast and advanced cancer patients 
have explored important areas of personal experience and the meaning of cancer, 
none of those qualitative studies of breast cancer patients has focussed primarily on 
HRQoL as a multidimensional construct and has explored the meaning of HRQoL 
as a research question. None of these studies has been conducted in the context of 
clinical trials and therefore used very diverse samples of patients. In addition, in 
most of the studies the primary purpose has been the possible implications for 
nursing theory and practice.  Therefore, a qualitative study of advanced breast 
cancer patients’ subjective meanings of HRQoL, conducted by a psychologist and 
in the context of a clinical trial, is important and useful.
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2 AIMS  
The general aim of this thesis was to investigate the feasibility of extracting valid 
information on patients’ HRQoL by using various types and sources of data, and to 
find out how these different data sets contribute to the knowledge of breast cancer 
patients’ HRQoL.   
The specific aims were: 
To describe and compare the HRQoL findings of a phase III multicentre trial 
comparing docetaxel (T) to sequential methotrexate and 5-fluorouracil (M-F) in 
order to find out whether either treatment has a superior benefit in terms of HRQoL
and to explore HRQoL changes over time.  
To demonstrate empirically the importance of the exact timing of HRQoL 
assessments.
To estimate the contribution of physical performance and different toxicity 
variables in explaining the patients global QoL. To evaluate the agreement 
between the information on side-effects scored by the physician and the patient.  
To study whether baseline HRQoL or changes in HRQoL scores from the baseline 
or both together are prognostic for the time to disease progression or overall 
survival.
To gain a deeper qualitative understanding of the personal meanings that are related 
to patients’ HRQoL. To identify possible important dimensions of HRQoL not 
captured by traditional psychometric methods. 
3 METHODS 
3.1 Patients in studies I-IV  
The patients in this study were required to have histologically proven breast cancer 
that had progressed during or after first line anthracycline treatment for advanced 
disease or that had relapsed within 12 months after discontinuation of adjuvant 
anthracycline therapy.  The ages of the patients were required to be > 18 and < 70 
years with a performance score of < 2 and with normal values of white blood cells 
(>3 x 109/L), platelets  (> 100x109/L), serum bilirubin, and serum creatinine.  
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Patients were ineligible if they had more than one previous chemotherapy regimen 
for advanced disease  (with the exception that multiple endocrine treatments and 
radiotherapy were allowed), prior treatment with taxanes, any concurrent serious 
medical illness, cerebral or leptomeningeal metastases or a history of other 
malignancy except contra lateral breast cancer, basal carcinoma of the skin or in 
situ cervical cancer. 
The study was an open randomised phase III study comparing docetaxel to 
methotrexate-5- fluorouracil after anthracycline failure. Cross-over to the 
alternative treatment after relapse was recommended. In all, 283 patients with 
metastatic breast cancer were randomised into this study between December 1994 
and October 1997 from 22 centres in Scandinavia, Estonia and Poland.  From the 
283 patients, one patient in the M-F group was later found to have no recurrence 
and was excluded from all the analyses. Oral and written consent by the patient was 
mandatory for both the trial and the HRQoL measurement. The clinical study and 
the HRQoL studies were approved by the ethical committees with jurisdiction for 
the participating centres.   
3.2 Patients in study V 
In Finland, 32 consecutive breast cancer patients were asked to participate in this 
qualitative study from the study population participating in randomised phase III 
study comparing docetaxel to methotrexate-5- fluorouracil.   Two agreed to 
participate, but died after the first course of treatment.  One patient was Swedish 
speaking and therefore could not participate in the study. Three patients  refused to 
participate and 2 patients agreed to participate, but constantly cancelled the 
appointment for the interview, and therefore the researcher got the impression that 
they were nevertheless not willing to participate. Altogether, 25 patients 
participated in the study.  
3.3 Procedures 
3.3.1 Studies I, II,III and IV 
In order to maximise compliance and minimise error variance due to uncontrollable 
differences in the timing or in the external conditions of the assessments, QoL data 
acquisition was integrated into the clinical routine of the patients. The questionnaire 
was administered at the hospital, whenever possible in a room where the patient 
was not disturbed.  The responsible study nurse, or failing that, another member of 
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the staff, gave the patient the questionnaire and demonstrated for her the two 
different answering modes (yes-no, and the scales) in order to make sure that the 
patient understood the task correctly.  The patient was asked to answer all the 
questions by choosing the best alternative available even if no alternative offered an 
exact match.  Before answering, the patient was informed about the confidentiality 
of the answers; it was explicitly stated that they would not be shown to the 
physician in charge of the treatment.  When all questions had been answered, the 
questionnaire was put in a sealed envelope that had been placed in front of the 
patient.  The envelope was then mailed to the centre responsible for the SBG9404 
(Scandinavian Breast Cancer Group) data entry (Helsinki).  The responsible study 
nurses had participated in a one-day training session during which they were given 
a checklist of how to organise and monitor the HRQoL measurements. 
The first, i.e., the baseline measurement, was made immediately preceding the 
administration of the first treatment; hence, when filling in the form, the patients 
were aware of which treatment they would recieve.  During treatment, HRQoL 
assessments were to be completed on day one of every treatment cycle, before the 
administration of the treatment. A time window of –4 to +0 days (anchored to the 
administration of the treatment) was determined for an acceptable assessment.  This 
window was accepted on pragmatic grounds: many patients visited the clinic a few 
days before they received the treatment and completed the questionnaires during 
that visit.  Allowing for –4 days made it possible to include those patients whose 
visits were interrupted by a weekend;  in contrast, delaying the assessment until 
after the treatment was not acceptable, since receiving treatment was expected to 
produce effects that would have an immediate impact on HRQoL. HRQoL data 
collection was continued as long as the randomised treatments continued i.e., until 
the cross-over.  
3.3.2 Study V 
Participating in the study was voluntary. It was especially emphasised that 
participating is optional and does not influence treatment decisions or clinical trial 
participation. It was also stressed that the research is conducted on behalf of the 
University of Helsinki, Department of Psychology, not on  behalf of the 
Department of Oncology. Confidentiality was stressed in the written patient 
information form and always discussed before the interview. It was stressed that the 
interview was conducted for research purposes and was strictly confidential 
(including physicians and nurses in the clinic). The only person who will ever see 
the content of the interviews as such is my supervisor in the department of 
31
psychology and, even so, the patients’ personal particulars will remain confidential. 
Permission for tape-recording was asked before starting the interview. Oral and 
written consent was mandatory for the interview. The study was approved by the 
ethical committee of the Helsinki University Hospital.   
One of the criticisms of single interviews is that HRQoL issues may cause distress 
to patients and cannot be followed up.  For this reason, the patients were given the 
opportunity to contact the researcher at any time if desired or needed; none of the 
patients got in touch with the researcher outside the interview. The interviews took 
place in a quiet hospital room that was not the physicians’ office. The timing of the 
interviews was after the second or third treatment course, by which time the 
patients had had personal experience of the randomised treatment.   
For the opening question, patients were asked to tell about themselves, their family, 
their current situation in life and to describe their course of illness. A semi-
structured interview format was used. After the opening question, the structure of 
the interviews broadly followed the structure of the HRQoL questionnaires 
encompassing global ratings of HRQoL , physical, emotional, social, cognitive and 
role functioning. However, the interviews were conducted in an open manner, 
giving the patients the freedom to discuss important issues in their own way.  
The original material consisted of 25 audiotaped interviews, with a mean the 
duration of about 60 minutes. The researcher who transcribed them verbatim for 
analysis, also conducted the interviews. The AtlasTi 4.1 for Windows software 
package was used for analysis (www.atlasti.de, 2003).  
3.4 Instruments  
3.4.1 EORTC QLQ-C30 
To assess HRQoL, we used the EORTC QLQ-C30 (The European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire C30) (Aaronson 
et al., 1993). This questionnaire has been developed to cover aspects of life 
particularly relevant to cancer patients. It has been translated and validated into 49 
languages and has been used in more than 3,000 studies worldwide. The 
questionnaire is designed to assess the patients’ physical functioning (PF), role 
functioning (RF), cognitive functioning (CF), emotional functioning (EF), social 
functioning (SF), global quality of life (GQL),  pain (PA), fatigue (FA), 
nausea/vomiting (NV) and,  means of multi-item scales, and disease- and treatment-
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related symptoms by means of single items: (dysopnea DY, insomnia (SL), appetite 
loss (AP), constipation (CO), diarrhea (DI) and financial difficulties (FI). 
The first generation of the core questionnaire, the EORTC Quality of Life 
Questionnaire-Core 36 (QLQ-C36) was developed in 1987 (Aaronson et al., 1993). 
The QLQ-C36 questionnaire was designed to be cancer specific, multidimensional 
in structure, appropriate for self-administration, and applicable across a range of 
cultural settings. The subsequent versions of the core questionnaire were the 
EORTC QLQ-C30 (version 1.0), the EORTC QLQ-C30 (+3), the EORTC QLQ-
C30 (version 2.0) and the EORTC QLQ-C30 (version 3.0). The EORTC QLQ-C30 
(version 3.0) is the most recent version. We used the  validated version 2.0 in 
Finnish, Swedish, Norwegian, Danish and Polish; the Estonian translation EORTC 
QLQ-C30 was made ad hoc. 
The EORTC QLQ-C30 has been shown to be a reliable and valid instrument 
(Hjermstad, Fossa, Bjordal, & Kaasa, 1995; McLachlan et al., 1998; Osoba et al., 
1994; Sigurdardottir et al., 1996). The usefulness of the instrument in a clinical 
setting depends on its ability to detect clinically significant differences in terms of 
sensitivity (the ability to detect differences between groups) and in terms of 
responsiveness (the ability to detect changes over time within the patient) (Fayers 
& Hand, 2002). The EORTC QLQ-C30 has been  shown to have the ability of 
detecting changes (Osoba et al., 1994). 
There are some suggestions on how to interpret the clinical significance of the 
results of the EORTC QLQ-C30. Various investigators using a variety of HRQoL 
instruments have found that an absolute change of 10% or more on HRQoL scores 
corresponds to a moderate change in the  average patient’s condition (Fayers, 
2001). This seems to be applicable to the EORTC QLQ-C30, as well. According to 
Osoba, the clinically significant changes on a scale of 0-100 are the following: a 
difference of 5 to 10 indicates a small change either for the better or the worse; a 
difference of 10-20 stands for "moderate" change, and a difference greater than 20 
for "very much" change (Osoba et al., 1998).   The EORTC QLQ-C30  has 
population-based reference data  from the following countries: Denmark, Norway, 
Sweden and Germany (Hjermstad, Fayers, Bjordal, & Kaasa, 1998; Klee, 
Groenvold, & Machin, 1997; Michelson, Bolund, Nilsson, & Brandberg, 2000; 
Schwarz & Hinz, 2001). There are also reference values available by cancer site 
and stage (Fayers et al., 1998).  All these together provide important aid for the 
interpretation of results from EORTC QLQ-C30 scales.  
33
3.4.2 Medical data 
Physicians completed the trial specific case report forms (CRF) before each 
treatment cycle. Toxicity (i.e., nausea/vomiting, stomatitis, diarrhoea, alopecia, 
infection,  allergy, skin changes and local and other symptoms of toxicity, i.e. nail 
changes, fatigue dermatitis, neuropatia, oedema)  from the previous chemotherapy 
cycle and the WHO performance status (WHO PS) were assessed before each 
treatment by physician interviews. Toxicity and response evaluation were evaluated 
according to WHO criteria (Miller et al., 1981). The toxicity grades ranged from 0 
(absent) to 4 (life- threatening). In these data, the WHO performance score ranged 
from 0 (normal activity),  1 (symptoms but ambulatory), 2 (in bed < 50% of waking 
time) to 3 (in bed > 50% of waking time). All adverse reactions and reasons for the 
discontinuation of treatment were collected on the clinical research forms. Overall 
survival and time to disease progression were calculated from the day of 
randomisation.
3.5  Statistics  
In our study, even in the light of the most recent guidelines in comparison with
reports published since 1999, the data meet a high standard of validity and 
reliability.  The compliance (percentage received of expected forms) of the study 
was 96% and the overall compliance for the first 14 cycles was 89.8%. When forms 
were completed outside the accepted time window (–4 to +0 days) were excluded, 
the corrected compliance was 82.4%. The compliance level of our study is one of 
the highest reported in the field and shows that high compliance, even in patients 
with advanced cancer, can be achieved. The HRQoL data were available for 245 
patients in this analysis: TABLE 1 
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Table 1 Number of correctly timed EORTC QLQ-C30 questionnaires received by 
treatment group and treatment cycle with docetaxel (T) methotrexate and 5-
fluorouracil (M-F) 
Following the instructions in the EORTC QLQ-C30 scoring manual, a linear 
transformation to a 0 to 100 scale was carried out (Fayers, Aaronson, Bjordal, & 
Sullivan, 1995).   A higher mean score for functional scales (physical functioning 
(PF), role functioning (RF), cognitive functioning (CF), emotional functioning 
(EF), social functioning (SF) and global quality of life (GQoL)), reflects a higher 
level of functioning, but a higher mean score for symptom scales,  (pain (PA), 
fatigue (FA), nausea/vomiting (NV)), and for disease- and treatment-related 
symptoms i.e.  the single items: (dyspnoea DY, insomnia (SL), appetite loss (AP), 
constipation (CO), diarrhoea (DI) and financial difficulties (FI)) reflects more 
symptoms or problems.   
The percentages of missing values for single items were the following:  0.8% of all 
items, ranging between 0.3% to 1.4% across the items. They were replaced by 
values calculated as suggested in the QLQ-30 manual (Fayers et al., 1995). 
Treatment cycle T M-F
1 Baseline 129 116
2 106 96
3 104 86
4 86 64
5 80 49
6 66 40
7 58 33
8 37 30
9 39 21
10 17 15
11 11 13
12 9 9
13 7 6
14 6 5
15 7 5
16 4 4
17 3 2
18 1 1
19 1 1
20 1 1
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3. 5. 1 STUDY I 
The means and standard deviations were calculated for each domain of EORTC 
QLQ-C30.  The means of the two treatment groups on all scales were compared at 
each point of assessment i.e. at the baseline (i.e. 1st cycle), 2nd, 3rd , 4th, 5th, and 6th
treatment cycles.  
Mean change scores were selected as an additional outcome measure. The 
calculation of change scores was made by subtracting the mean scores from the 
cycles 2 to 6 from the patients’ corresponding baseline scores. 
The Mann-Whitney U test  was used to investigate the statistical significance of the 
differences between the two treatment arms at each point of assessment.   
3. 5. 2 STUDY II 
In the clinical database, separate variables were used to indicate day 1, i.e., the 
starting date of every treatment cycle and, in the QoL database, a separate variable 
was used to indicate the actual date of every QoL assessment.  By comparing these 
dates in these two datasets, it was possible to identify measurements performed at 
dates different from the prescribed ones.  
table 2 The number of correct and incorrect timings by treatment group and cycle   
incorrect correct incorrect correct
n n n n
Baseline 17 116 8 129
Cycle 2 12 96 9 106
Cycle 3 14 86 6 104
Cycle 4 12 64 6 86
Cycle 5 5 49 1 80
Cycle 6 7 40 6 66
Cycle 7 2 33 2 58
Cycle 8 30 1 37
Cycle 9 1 21 39
Cycle 10 2 15 1 17
Cycle 11 13 11
Cycle 12 2 9 9
Cycle 13 2 6 1 7
Cycle 14 1 5 6
Total 77 583 41 755
M-F T
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In order to evaluate the difference between correctly timed and incorrectly timed 
HRQoL assessments, the mean scores of EORTC QLQ-C30 scale points were 
compared. The two treatment groups were analysed separately since it was 
expected that erroneous timing might affect the patients’ responses differently 
because of the different toxicity profiles of the two treatments.  We chose to include 
in the analysis the first 14 treatment cycles, after which the number of patients 
became very small.   
We compared the ill timed and correctly timed assessments at the baseline, at 
which point the effects of dropout had not disturbed the similarity between the two 
groups and average over the cycles, because the number of ill timed assessments 
per treatment cycle was very small.  
T-tests were conducted to investigate statistical differences between incorrectly and 
correctly timed assessments. A significance level was set at 5%.  
3. 5. 3 STUDY III 
To study the correlation between the EORTC QLQ -C30 scales and the WHO PS as 
well as  between the EORTC QLQ-C30 scales and the corresponding WHO 
toxicity scales, Spearman’s rank correlation coefficients were used.  
Multiple linear regression analysis was conducted to investigate the impact of 
toxicity variables on the global QoL. In these analyses, the WHO PS and the 
toxicity variables were defined as independent variables. Multivariate models were 
created by using general linear modelling with a stepwise procedure.  A 
significance level of P <=.01 was set.   
3 .5. 4  STUDY IV 
All baseline EORTC QLQ-C30 variables were dichotomised at the median to yield 
“good” or “poor” scores. Change scores were calculated indicating change in the 
EORTC QLQ-C30 between the baseline (i.e., the first measurement) and the 3rd
treatment course. The 3rd  course was selected because patients had had experience 
of the treatment and attrition from the study was minimal. This procedure ensured 
the most representative samples in both treatment groups. Extreme baseline scores 
(i.e., 0 or 100) were omitted from analysis, since in these patients, HRQoL could 
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change in only one direction. The percentage of cases omitted from the analysis for 
that reason  depended on the scale and varied from 11% for social functioning to 
45% for role functioning with a mean of 36%. The change data was available for 
173 patients. 
Time to disease progression (TTP) and overall survival (OS) were calculated from 
the day of randomisation.   
Differences in TTP and OS were tested with the log-rank test. Survival curves and 
probabilities were estimated using the Kaplan-Meier technique. Univariate and 
multivariate analyses were performed with the Cox proportional hazards regression 
model to explore the relationship between baseline QoL variables and TTP as well 
as OS. For the multivariate analysis, Cox regression analysis was performed using 
the stepwise method and both forward and backward procedures were used, 
yielding the same results. The importance of single prognostic factors was assessed 
using the p value of the Wald chi-square statistics, the hazard ratio and its 95 % 
confidence interval for both TTP and OS.   
To explore the relationship between the change in HRQoL variables and TTP as 
well as OS, the Cox proportional hazards regression model was used for univariate 
analysis.  
A significance level of 1% was chosen, because of the multiple testing. 
3. 5. 5 STUDY V  
A qualitative research paradigm was applied and, more precisely, a 
phenomenological research method was chosen to explore the experiences of the 
women (Giorgi & Aanstoos, 1996). The method contains 4 essential steps: (1) The 
investigator reads the entire description to obtain a general idea of the whole 
statement. By thoroughly reading and rereading each interview file, the researcher 
acquires an idea of the women’s experiences. To gain a general sense after reading 
is the basis for the next step.   (2) The discrimination of meaningful units from a 
psychological perspective is done and with a focus on the phenomenon being 
investigated. In this step, the subjects’ language is not changed in any way. Since it 
is impossible to analyse the entire interview file simultaneously,  it must be broken 
down into manageable units.  The meaningful units in this phase of study were at 
first relatively broad and followed the broad areas of the interview.  The researcher 
repeated this phase many times and as a result, the meaningful units that emerged 
as a consequence of the analysis sharpened and narrowed. These meaningful units 
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do not exist in the text as such, rather only in relation to the attitude or viewpoint of 
the researcher.  (3) The subjects’ everyday expressions were transformed into 
psychological language. These transformations were necessary because we wished 
to elucidate the psychological aspects in depth. This is essential for understanding 
the phenomena being researched.  (4) Transformed meaningful units were 
synthesised  into a consistent statement. The criterion was that all the meanings of 
the transformed meaningful units at least implicitly contain one consistent 
statement.  This can be referred to as the structure of the experience. In the present 
study, the structure of the experience broadly followed the architecture of the 
EORTC QLQ-C30.   
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4 SUMMARIES OF RESULTS Studies I-V 
4.1  STUDY I: Quality of life in patients with metastatic breast cancer 
receiving either docetaxel or sequential methotrexate and 5-
fluorouracil. A multicentre randomised phase III trial by the 
Scandinavian Breast Group 
This study was to compare the effects of two alternative treatments on HRQoL and 
to evaluate the possible gains offered by the alternative treatments during the six 
treatment cycles.  
Baseline HRQoL data were available for 245 patients: 130 in the  docetaxel (T) 
group and 115 in the methotrexate and 5-fluorouracil (M-F) group. Data were 
available for both treatment groups for 20 cycles of treatment, however, due to 
sample attrition, the groups after 6  cycles were no longer comparable.  
Table 3. Reasons for sample attrition at cycle 6   
The mean baseline scores of the study were compared against reference values of 
breast cancer patients with advanced disease produced by the EORTC QoL study 
group (Fayers et al., 1998) and against the normative values of the general Swedish 
population (women aged 50-59) (Michelson et al., 2000). This data was chosen 
because the median age of the patients of our study population was 51 and  the 
Swedes were the largest sample population in this data (82 of 282 patients were 
randomised in Sweden.)  
T M-F
QoL questionnaires recieved 66 40
QoL Protocol violation 13 12
Treatment discontinued due to
       Progressive disease 36 74
       Death 6 5
       Adverse event 8 2
       Patient refusal 9 3
       Other 3 3
       Missing 1 1
Total attrition due to treatment discontinuation 63 88
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Figure 1. Baseline the mean functional scale scores by treatment group, M-F= 
methotrexate and 5fluorouracil, T = docetaxel,  ABC= reference values for advanced breast 
cancer patients, Swedish norms = Swedish normative values for women 50-59 years of 
age. The number of questionnaires is indicated by n.  Higher scores mean better 
functioning or better global QoL .  
Hence, the data compared against the available reference values seem plausible. 
The data are coherent with that of advanced breast cancer patients.  There are 
considerable and clinically significant differences in the subscales of physical, role, 
emotional and social functioning as well as global QoL scales compared against the 
average scores of 50-59 year old Swedish women.  
In the longitudinal analysis of six courses of the treatment, both treatment groups 
showed clinically significant improvement in emotional functioning from the 
baseline, with a  statistically significant difference favouring the M-F group at 
treatment cycles 5 (T 73,6 and M-F 81.6 P= 0.028)  and 6 (T 72,9 and M-F 86,3 p= 
0,002). In the T group, the scores on the other functional scales remained stable 
throughout the first six cycles. There were significant differences favouring the M-
F group on the social functioning scale at treatment cycle 6 and on the Global QoL 
scale at treatment cycles 5 (T 52. 2 and  M-F 64.4; p= 0.004 and 6., (T 49.1  and . 
M-F 63.5 p= 0.001). (Figure2)  
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Figure 2 Functional scale mean scores by treatment group from baseline to 6th  treatment 
cycle 
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Figure 3 . Baseline the mean symptom scale and single item scores by treatment group ( 
T= docetaxel M- merhotrexate fluorouracil), ABC= reference values for advanced breast 
cancer patients, Swedish norms = Swedish normative values for women 50-59 years of 
age. Higher scores mean more problems or symptoms.
Again, when comparing our data against these reference values available, the data  
seems to be reliable. 
There were significant differences in mean scores  at the baseline, as the T patients 
suffered  significantly more from appetite loss (T  24.3  versus  M-F 15.9 ; p=0.02) 
and  M-F patients reported more nausea/vomiting at treatment cycles 2 (T 8.3  
versus  M-F 12.8; p= 0.013), 3 (T 6.3  vs. M-F 12.0; p=0.002)  and 4 (T 4.3  versus 
M-F 11.4;  p=0.002).  At treatment cycle 6, the T group suffered more from the 
following symptoms: fatigue (T 43.6  versus. M-F 34. 0 ; p=0.04), dyspnoea (T 
33.3  versus. M-F 22.5   ; p=0.017) and insomnia (T 25.3 versus  M-F 15.8 p=0.04).  
The potential HRQoL gains offered by the two treatments were evaluated by 
choosing the mean change scores as an additional measure of outcome. The 
calculation was made by subtracting the mean scores from the cycles 2 to 6 from 
the patients’ baseline score. The median values of the change scores remained 
stable, with the exception of emotional functioning and fatigue; however, the 
variance was higher in the  group. The change scores showed no differences 
between the treatment groups.  
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To summarise: Both treatment groups showed improvement in emotional 
functioning after the baseline.   There were some significant differences in HRQoL 
favouring M-F patients, with the exception of nausea/ vomiting. During the 6 
cycles of treatment all functional scale scores remained stable in the T group. In the 
M-F group there was an increase in the social functioning scores at treatment cycle 
6 and also on the Global QoL scale at treatment cycles 5 and 6. There were some 
significant differences in symptom / single item scales, which corresponded well to 
the toxicity profiles of the different treatments; however, there were no differences 
when mean scores were compared.  
4.2 STUDY II Timing of quality of life (QoL) assessments as a source 
of error in oncological trials 
This study was to give an empirical demonstration of the importance of the exact 
timing of HRQoL measurements in connection with clinical trials comparing 
treatments with cyclic side effects and  to estimate of the nature and the magnitude 
of the error produced by incorrect timing.  
At the baseline in the M-F group there was a significant difference between 
incorrectly and correctly timed assessments on the nausea/vomiting scale with ill 
timed assessments showing more symptoms, 18 scale points vs. correct 7 scale 
points for the correctly timed assessments (p= 0.006). In the T group, the 
statistically significant difference between incorrectly and correctly timed 
assessments was found in physical functioning (PF), with ill timed assessments 
showing better physical functioning,    85 vs. 65 for the correctly timed assessments 
( p= 0.047).
However, in both treatment groups on several other scales there was a clinically 
significant difference (10 or more points) between correctly and incorrectly timed 
assessments.  In the M-F group on the physical (PF) and the social (SF) functioning 
scales, the difference between incorrectly and correctly timed assessments was 10 
points (PF correct 65, incorrect 55; SF correct 71, incorrect 61, p=ns) and in the T 
group this was found for emotional functioning (correct 62 vs. incorrect 74; p=ns), 
social functioning (correct 71 vs. incorrect 83; p=ns), global QoL (correct 53, 
incorrect 66; p=ns), fatigue (correct 40 vs. incorrect 25; p=ns), and pain (correct 33 
vs. incorrect 20; p=ns) scales.   
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The results over the first 14 cycles showed that in the M-F group there was a 
significant difference between incorrectly and correctly timed assessments for  
physical functioning, global QoL , nausea/vomiting, insomnia, appetite loss and 
constipation scales. These significant differences were very consistent; the scores of 
ill timed assessments were worse on the functional scales, and on the symptom and 
single item scales, all significant differences were in the same direction, with ill 
timed assessments producing more symptoms. In the T group the findings were not 
consistent. The only significant difference found on the functional scales was found 
on the physical functioning scale with an incorrect assessment indicating better 
physical functioning. On the symptom and single item scales, the significant 
differences went in different directions: for dyspnoea the correctly timed 
assessment reported more symptoms, whereas on the insomnia scale the patients 
reported more problems if assessment was made outside the time window. 
Table 4 Mean scores and difference in mean scores  for correct and incorrect timing by 
treatment group by trial.
To summarise:   Within both treatment groups, the erroneous timing of HRQoL 
assessments produces significant differences on some HRQoL scales. The results of 
this study demonstrate that the inaccuracy of the timing of HRQoL measurements 
Incorrect Correct difference Incorrect Correct difference 
Functional scales (n=77) (n=583) Incor-Cor. p (n=41) (n=755) Incor-Cor. p
Physical 59.9 66.4 -6,4 0.013 73.7 63.4 10.3 0.006
Emotional 75.5 77.2 -1,7 ns. 69.1 71.6 -2.5 ns.
Social 67.8 74.1 -6,3 ns. 77.6 69.2 8.4 ns.
Role 61.0 64.3 -3.3 ns. 63.8 62.5 1.3 ns.
Cognitive 82.2 85.2 -3.0 ns. 79.7 83.8 -4.1 ns.
Global QoL 51.2 61.1 -9.9 0.000 59.6 53.8 5.8 ns.
Symptom/single item scales
Fatigue 46.3 39.5 6.8 0.022 38.1 40.2 -2.1 ns.
Nausea / vomiting 16.2 9.2 7.0 0.000 4.9 6.9 -2.0 ns.
Pain 23.8 25.6 -1.8 ns. 22.8 24.0 -1.2 ns.
Dyspnoea 25.5 25.6 -0.1 ns. 17.1 28.1 -11 0.011
Insomnia 29.4 22.2 7.2 0.005 33.3 25.8 7.5 0.047
Appetite loss 24.2 17.4 6.8 0.028 15.4 17.2 -1.8 ns.
Constipation 21.6 15.1 6.5 0.011 15.4 11.2 4.2 ns.
Diarrhoea 16.0 15.1 0.9 ns. 17.1 15.3 1.8 ns.
Financial difficulties 16.2 22.1 -5.9 ns. 24.1 29.8 -5.7 ns.
M-F T
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seriously jeopardizes both the reliability and the validity of the findings, and 
therefore must  be carefully controlled and reported.  
4.3 STUDY III Physical performance, toxicity, and quality of life as 
assessed by the physician and the patient 
The specific aims of this study were the following : (1) To find out the correlations 
between the physician-assessed WHO performance status and different domains of 
patient-assessed HRQoL.  The Spearman rank correlations between physician-
assessed physical performance and patient- assessed HRQoL in functional scales 
were the following: physical functioning (varying from the baseline to treatment 
cycle 6)  -0.49; -0.52; -0.56; –0.59; – 0. 38; - 0.59 and -0.49;  global QoL (from the 
baseline to the 6th cycle)   -0.31; -0.29; -0.35; -0.45; -0.48; -0.41; social functioning
-0.30; -0.33; -0.39; -33; -0.42; -0.31; role functioning -0.32; -0.39; -0.37; -0.41; -
0.42; -0.22; emotional functioning -0.14; -0.15; -0.14; -0.19; -0.19; -0.30; and
cognitive functioning -0.19; -.16; -0.12; -0.15; -0.26; -0.18.  
(2) To explore the agreement between nausea/vomiting and diarrhea toxicity 
assessments made by the physician and the patient.  The correlations for both these 
toxicity scales were moderate varying between 0. 46 and 0.56  for nausea/vomiting, 
with the exception of nausea/ vomiting at treatment cycle 4 in which the correlation 
was 0. 36. The diarrhoea toxicity correlation varied from 0.50 to 0.56.  
(3) To detect the contribution of physical performance and of different toxicity 
variables in explaining the patients’ global QoL. As a result of a stepwise linear 
regression analysis, the contribution of treatment toxicity to the global QoL scores 
was the following: having worse WHO physical performance, severe infection and 
nausea predicted worse a global QoL. These three variables explained 16 % of the 
variation in the global QoL  (F value =51; p= 0.0001).  
To summarise: Variation  was found in the correlations between physician assessed 
PS and the different the  EORTC QLQ-C30 scales.  The strongest correlations were 
between the EORTC QLQ-C30 scales and the WHO PS were found in physical 
functioning and in global QoL with fairly low correlations in emotional functioning 
and cognitive functioning. The toxicity assessed by the physician and the patient 
had moderate correlations. When using physical performance and toxicity as 
independent variables to explain the variation of global QoL, 84% of the variance 
remains unexplained.  
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4.4 STUDY IV Prognostic value of quality of life scores for the time 
to disease progression (TTP) and overall survival time (OS) for  
advanced breast cancer 
This study was to examine whether HRQoL scores have prognostic value, or more 
precisely  
(1)  Wether baseline HRQoL or changes in HRQoL scores from the baseline or 
both were prognostic for TTP.  
The results of this study show that baseline HRQoL scores  had no prognostic value 
for the duration of TTP. HRQoL change scores from the baseline did not predict 
TTP.
This clinical study was a cross-over study and there was no significant difference in 
overall survival between the two treatment groups. This setting and the results of 
the study gave us an opportunity also to examine (2) whether baseline HRQoL or 
changes in HRQoL scores or both had prognostic value for overall survival (OS). 
In univariate analysis, more severe pain (8.5 months vs. 12.9 months p=0.0044) and 
fatigue (8.6 months vs. 14.5 months p=0.0008) at the baseline were predictive for 
shorter OS. There was borderline significance on the following scales:  global QoL 
(9.6  months vs. 14.8 months p=0.0130), physical functioning (9.9 months vs. 13.3 
months p=0.0256), and appetite loss (9.9 months vs. 13.2  months p=0.015)  for 
predicting shorter OS.  In multivariate analysis, more severe pain at the baseline 
(p= 0.0020) was an independent predictor for shorter OS.  QoL change scores from 
the baseline QoL had no predictive value for OS. 
Moreover, the aim was to study  (3) whether the WHO performance status had 
independent prognostic value for TTP or OS or both.  The WHO performance 
score was associated with TTP and OS, and a better WHO performance score 
predicted a longer TTP (WHO 2  vs. WHO O  p= 0.0092  and  WHO 1  p= 0.029) 
and longer OS ( WHO 2  vs. WHO O  p= 0.0044  and  WHO 1 p= 0.0073). 
Table 5 Median TTP and OS by WHO performance score 
Variable n Median time to progression in months Median overall survival in months 
WHO 0 72 5.0 12.9
WHO 1 140 4.8 11.3
WHO 2 32 3.0 7.1
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To summarise: The results suggest that HRQoL scores have no outstanding 
prognostic value. However, pain and the WHO performance score have a predictive 
value for OS and the latter for the TTP as well.   
4.5 STUDY V The meaning of quality of life in patients being treated 
for advanced breast cancer: A qualitative study  
The aim of the study was to gain a deeper qualitative understanding of the personal 
meanings that are related to patients’ HRQoL and to complement the findings of 
our earlier studies from a predetermined study setting using the EORTC QLQ-C30.   
The present findings show that cancer and its treatment limited the patients’ 
physical functioning. impacting on the patients’ ability to perform their usual 
activities of daily living, such as driving, walking, housework, family and leisure 
activities and self care.  These limitations were translated into dependency on 
others and led to decreased feelings of autonomy (referring to the extent of control 
over life that the patient subjectively feels). The patients tended to ensure their 
autonomy by engaging in less strenuous activities or by changing their internal 
standards. The feeling of being able to do something useful for the family became 
important. The treatment was perceived as an enemy and many felt that they 
suffered because of the treatment. At the same time the treatment meant hope, not 
only for themselves, but also for the family and for future cancer treatments. 
Treatment adherence meant perseverance and stopping the treatment meant caving 
in and dying.  
The patients’ ability to carry out roles and responsibilities became restricted due to 
changes in appearance and decreased physical condition. The limitations on role
functioning were difficult to accept and feelings of uselessness became 
predominant, especially when they had to face the reality of being on sick leave or 
a disability pension. Most women used to work outside the home, and therefore felt 
useless in society, when forced to give up their employment.   
The patients’ social functioning was shattered by changes in lifestyle and 
appearance. Changes in appearance complicated keeping up normal interface, since 
many patients did not want to reveal their illness. By not telling friends about their 
cancer, they ensured that they would maintain their relationships as they had always 
been.  Changes in lifestyle and appearance often led to retreating from social 
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relationships with colleagues, neighbours and distant friends. The patients 
maintained control of to what extent their illness was recognised in social 
relationships, which was important to their feelings of autonomy. Even social 
isolation was used in controlling the illness experience and maintaining autonomy.  
The importance of being able to sustain reciprocal relationships was often stressed. 
A close family was the main source of instrumental and emotional social support, 
but also a major source of concern.   
The meaning of emotional functioning crystallised around the ability to enjoy life 
day by day and to persevere through treatment even though most patients reported 
feeling bad-tempered, feeling down, being epressed and being less tolerant than 
they had been previously. Patients used denial to sustain emotional functioning and 
to ensure the capability of feeling joy. As a positive consequence of the illness 
experience, feelings of personal growth were expressed. The patients often felt that 
the illness also meant the capability to enjoy things more fully and more 
sensitively. 
The patients’ difficulties with cognitive functioning were more characteristic of 
anxiety. Some patients complained of difficulties in concentration, and beginning 
things was especially difficult. The importance of untouched cognitive functioning 
was the ability to escape from the illness experience in that  patients were able to 
concentrate on leisure activities, for example, on reading, and for those who 
worked, on being able to complete their work.    
Global QoL was dependent on the patients’ ability to live as normally as possible, 
to maintain reciprocal relationships and to control their illness experience. 
Normalcy in life was expressed in the terms that the illness would chang their 
lifestyle as little as possible. However, the patients were aware that they were not 
able to maintain a normal life and, therefore, being able to participate in the same or 
similar activities they took part in before the breast cancer diagnosis or current 
treatment were described as moments of a good life. Normal mutual relationships 
were seen to be important for maintaining a good QoL while not being able to have 
them indicated a poor QoL. The patients’ ability to control the illness experience 
was the most striking indicator of maintaining a good QoL. Patients used various  
ways to control the experience of feeling ill.  
The three dominant themes that emerged from the data were clearly linked around 
the other dimensions of experiences of HRQoL; that is, the patients’ ability to 
control the illness experience, experienced personal growth and hope. The first was 
49
the patients´ ability to control the illness experience, which  stood out as the single 
most important meaning of the patients’ physical,  social, emotional and role 
functioning as well as their global QoL. The patients’ ability to compensate for 
decreased physical functioning by engaging in less strenuous activities can be 
interpreted as an effort to safeguard their feelings of autonomy. The interviews 
showed that the patients’ need to control the illness experience appeared as 
decreased social functioning, of which the extreme form was social isolation. The 
change from being needed to needing someone was difficult to accept and led to 
decreased feelings of autonomy.  Emotional reactions towards the illness 
experience were controlled by using denial. Activities and events during which 
patients were able to hold on to feelings of autonomy were characteristic in 
describing a good QoL, because they offered an escape from the reality of being ill. 
The importance of controlling feelings of autonomy was evident in the patients 
HRQoL; however, the means of ensuring feelings of autonomy varied from patient 
to patient. 
Another meta theme that emerged from the data was the patients’ changes in 
overall life perspective. Patients restructured their view of themselves. They felt 
that the illness experience also resulted in positive effects in their lives. They were 
more able to put the impact of events in a proper perspective and to focus on day to 
day living instead of the future.  The patients attributed these changes to personal 
growth.  Feelings of personal growth were important interpretations of the illness 
experience, especially in improving self-esteem. 
Hope emerged as the third meta theme in the present study. Hope and especially not 
losing hope were central to the patients’ HRQoL. Patients had to hold on to feelings 
of hope even though they seldom had high hopes for recovery, but rather hope for 
better physical condition, hope for response to the treatment, hope for dying with 
dignity, hope for  sufficient pain control, hope for being able to share important 
family occasions. To hold on to these feelings of hope, most patients did not want 
to know their possible survival time or to know what would happen after the 
progression of the disease. Treatment was seen as the greatest source of hope while 
termination of the treatment meant losing hope and giving up. Hope was seen to be 
important in determining the HRQoL for the patients themselves, but also for close 
family members. Hope for future cancer treatment was expressed as a motive for 
participating in the trial.
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5 DISCUSSION 
5.1 General discussion  
The consecutive series of studies in this thesis contributed towards a better 
understanding of HRQoL among women with advanced breast cancer. We have 
been able to produce comparisons on HRQoL between the patients receiving two 
different treatments, to assess the connection between clinical variables and 
HRQoL, and to evaluate the importance of the prognostic value of HRQoL. We 
have also focussed attention on one important methodological issue in HRQoL 
research and provided a deeper understanding of the subjective meanings that the 
patients have given to HRQoL.
One of the most important contributions of this study is that this thesis has made a 
serious attempt towards bridging the gap between qualitative and quantitative 
research in the field of HRQoL, providing information on how and why patients 
with advanced breast cancer experience HRQoL.    
We used the EORTC QLQ-C30 to measure HRQoL. This decision is well-
grounded, since the EORTC QLQ-C30 has been developed to assess the relevant 
aspects of the quality of life of cancer patients, especially in cancer clinical trial 
settings. In addition, at the time the protocol was written the EORTC QLQ-C30 
was the only instrument available with standardised translations for all of the native 
languages of the patients included in the study, with the exception of the Estonian 
translation, which was made ad hoc. Clinical research and data collection were 
performed according to the Declaration of Helsinki. The study protocol was 
approved in local ethical committees. Data collected by using clinical research 
forms was monitored against medical records by Aventis Pharma (formerly Rhone 
Poulenc Rorer).  
We have critically compared our study protocol with more recent guidelines and 
found it to be in harmony. It is worth noting that, in addition to the fact that this 
study is in harmony with recent guidelines, two additional important issues have 
been considered us and implemented, firstly, the confidentiality of the answers and 
secondly, the exactness of the timing of the HRQoL administration. In this study we 
wanted to stress the confidentiality of the answers. This was considered to be 
important in order to make it clear that the HRQoL study is independent from the 
physician in charge and, therefore, the answers in the HRQoL questionnaires 
cannot influence decisions on treatment. We did not want to interfere with the 
patient – physician relationship by evoking expectations that HRQoL issues are 
discussed in detail in the physician’s reception. We found this procedure to be 
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important for ethical reasons, as participating in the HRQoL study was voluntary 
and the data were collected for a scientific purpose.   
The response rate was 96% at the baseline and the overall compliance was 89%. 
Even after excluding ill-timed questionnaires, the overall compliance of the entire 
study was 82%.  This compliance is among the highest published. There might be 
several reasons for this a successful study design, an explicit study protocol, a one 
day training session for the study nurses, and a highly motivated staff, together with 
patient information which stressed confidentiality and explained the nature of the 
QoL study.  The use of a standardised questionnaire which has well-documented 
psychometric properties, the large sample size, the high compliance, and the 
baseline data being in harmony with the reference data available contribute greatly 
to the reliability and validity of studies I-IV . 
In our first study we found no major advantage for either treatment over the other 
(STUDY I). The results are in harmony with the earlier results reported from 
comparable studies concluding that there are no major differences in the HRQoL 
outcome between docetaxel and alternative regimens (Chan et al., 1999; Nabholtz 
et al., 1999; Nabholtz et al., 2003; O'Shaughnessy et al., 2002). HRQoL in the 
docetaxel group remained stable throughout the assessment points and increased in 
some domains in the M-F group, producing significant differences in some 
domains. Nevertheless, we might have expected that the toxicity of the docetaxel 
would have affected the results of HRQoL in a more pronounced way. The findings 
have relevance, since docetaxel has been shown to be the most effective treatment 
for advanced breast cancer thus far. It seems that survival gain is not reached at the 
cost of decreasing HRQoL. 
However, all longitudinal studies, particularly in palliative settings in which 
survival may be relatively short, are subject to difficulties of interpretation because 
of the selective attrition of the studied patient populations (Aaronson et al., 1993; 
Bernhard et al., 1998; Fairclough et al., 1998; Giaccone et al., 1998; Norris et al., 
2000; O'Shaughnessy et al., 2002; Sigurdardottir et al., 1996). The present findings 
are affected by an increasing number of non-random dropouts over time, which 
complicate the analysis and interpretation of longitudinal data.  The attrition due to 
disease progression was larger in the methotrexate and 5-fluorouracil  group (M-F).  
Consequently, the M-F patients remaining in the study through treatment cycle 6 
were a more select and less representative subgroup of the baseline study 
population than the patients remaining in the docetaxel  group. Our manner of  
handling the problem of selective dropout in group comparisons was to use 
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variables summarised within individuals, i.e. by also exploring the mean change 
scores.  In the present study, all statistically significant differences favouring the 
M-F group disappeared when comparing change scores over the treatment rather 
than the group means at specific points in time. We decided to conclude on the 
basis of the result of this study that the present HRQoL findings show no major 
advantage for either treatment over the other. Since there was large interindividual 
variance, especially in the docetaxel group, further studies are needed to better 
understand how the variation of the quality of life during treatment is related to 
patient physical functioning and toxicity. The findings of the first study were the 
prime motivation for our third study, namely exploring physical performance, 
toxicity, and quality of life as assessed by the physician and the patient. 
Assessing treatment toxicity and physical performance is important in evaluating 
the beneficial value or the burden of treatment.  Nevertheless, the present findings 
show that physical performance and toxicity explained only 16 percent of the 
variance in global QoL (STUDY III). The findings suggest that physician-rated 
clinical outcome variables do not necessarily measure patient-rated HRQoL . The
findings show weak to moderate correlations between the WHO PS and the 
different EORTC QLQ-C30 scales. Furthermore findings from earlier studies 
suggest that (Aaronson et al., 1993; McLachlan et al., 1998) the correlations are 
stronger for those EORTC QLQ-C30 scales that more directly address physical 
well-being.  It may seem surprising that correlations between toxicity assessments 
made by the patients and the physician were only moderate; however, these 
findings are consistent with more recent findings studying breast cancer patients 
receiving extremely toxic treatments (Brandberg et al., 2003). The weak 
associations between physician-assessed and patient-assessed treatment toxicity 
suggest that the two different manners of measurement are not assessing the same 
construct. Indeed, it is questionable whether detailed toxicity assessment is 
meaningful within HRQoL instruments. The development of new treatments is a 
continuous process and it may be an impossible task to continuously update, 
validate and translate the HRQoL instruments to adequately cover all different 
toxicity profiles of all treatments available. Rather, the development of HRQoL 
instruments might be steered towards an even better capturing of the psychological, 
social and cognitive aspects of HRQoL .
The findings of one study (IV) suggest that while HRQoL measurements are 
important as such; however, they have no great importance in predicting primary 
clinical endpoints such as overall survival or time to disease progression.  Despite 
the general conclusion made from the present study,  the results of this study  are in  
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harmony with the results that indicate that pain has prognostic significance for 
survival in advanced breast cancer patients (Kramer, Curran, Piccart, de Haes, 
Bruning, Klijn, Van Hoorebeeck et al., 2000). However, the general conclusion of a 
number of other studies is opposition to our study (Blazeby et al., 2001; Coates et 
al., 2000; Coates et al., 1997; Dancey et al., 1997; Jerkeman et al., 2001; Maisey et 
al., 2002; Montazeri et al., 2001; Seidman et al., 1995; Tamburini et al., 1996; 
Wisloff et al., 1997). 
Before concluding in either direction, it is worth noting that there are also some 
issues that must be taken into account when comparing our results to others. There 
are some paradoxical results in other studies e.g. the association between low 
emotional functioning and prolonged survival, which was practically strong in 
patients with  low global quality of life scores (Dancey et al., 1997). Furthermore, 
in one study higher role functioning was a positive prognostic factor in the 
univariate analysis; however, in the multivariate analysis, longer survival was 
associated with low role functioning (Roychowdhury et al., 2003). In a study by 
Kramer et.al. (2000),  different selection methods for multivariate analysis 
produced different results for response, with backward elimination including 
fatigue and good emotional functioning with dyspnoea as predictors of poor 
response to treatment.  
It is also important not to overlook the fact that in some of the studies the study 
population has been relatively small (Blazeby et al., 2001; Jerkeman et al., 2001). 
There has been some evidence that change scores from the baseline HRQoL can 
predict overall survival. It is questionable whether these results can be generalised 
because the number of patients alive in those studies was reduced (Blazeby et al., 
2001; Coates et al., 1992). In our study, we selected the 3rd  treatment course as the 
change value from the baseline in order to reduce thebias produced by selective 
dropout. In contrast to earlier studies, the results of our study, based on 173 
patients, suggest that the change from the baseline HRQoL does not predict either 
overall survival or time to disease progression. 
Although a large number of studies exists on HRQoL in cancer clinical trials, very 
few have incorporated information on HRQoL as a prognostic factor.  In 2001 there 
were about 110 studies including HRQoL assessment EORTC cancer clinical trials 
(Bottomley, Vanvoorden et al., 2003). Compared to the extensive use of HRQoL as 
a secondary endpoint in cancer clinical trials, there has been only a handful of 
studies addressing the issue of prognostic value. Furthermore, those  studies 
published have had positive findings. Hence, it can be argued that there may be a 
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publishing bias towards positive findings (Cleophas & Cleophas, 1999), because of 
the absence of other published negative findings. Disharmony in the findings and in 
the methods used, as well as the absence of negative findings, make a robust meta-
analysis difficult.
The methodological study of the timing of HRQoL assessment has focused 
attention on an important issue (STUDY II). The findings suggest that an erroneous 
timing of HRQoL assessments in oncological trials seriously jeopardises both the 
reliability and the validity of the findings. In all longitudinal and especially 
multicentre studies, some missing data due to various reasons are inevitable. 
However, the present study was carefully planned and monitored to avoid errors in 
timing, and the number of ill timed HRQoL assessments therefore was relatively 
low.  Nevertheless, within both treatment groups, a comparison between 
assessments performed within and outside the accepted time window produced 
statistically significant differences on some scales. The size of the differences 
observed was in some HRQoL domains 10 pts or more, which is considered 
clinically significant (Osoba et al., 1998).  Hence, within treatments, error variance 
due to incorrect timing is clearly  an important reliability issue. Another impact of 
this study is that the result of this study raises a question of how one should treat 
findings from earlier studies that either have specified their accepted time window 
for HRQoL measurements loosely, or have not specified it at all. On the basis of the 
present findings, we would be extremely cautious in letting clinical decision 
making be affected by any HRQoL findings of chemotherapy trials in which the 
issue of timing has not been treated with sufficient scientific rigor.   
We were able to compare patients’ HRQoL between the two treatment groups and 
to provide meaningful information on patients’ HRQoL by using the EORTC QLQ-
C30. Since the clinical study had cross-over setting,  it can be argued that we 
should have continued the  HRQoL data after the cross-over, in order to have even 
a rough estimation of  those patients’ HRQoL who dropped out of randomised 
treatment because of the progression of the disease. This can be considered a 
limitation of the present study. We, however, decided not to collect the HRQoL 
data for logistical reasons: the number of the patients who received cross over 
treatment was limited, and it was expected that while receiving the cross-over 
treatment many of those patients could not continue as outpatients. Furthermore, 
the study nurses were no longer responsible for those patients, i.e., the HRQoL data 
collection procedure was no longer qualified. In light of all this, the data collected 
after cross-over might not have been reliable.        
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The ability of a standardised QoL questionnaire to cover all important issues 
concerning the patients’ HRQoL must be considered limited. Correlative 
explanations of HRQoL are able to generalise the results over groups. However, the 
interpretation of a HRQoL result is always to some extent qualitative. Clinical 
significance is subjective and a matter of opinion, depending on values and 
opinions, which in turn differ among patients, clinicians and societies (Fayers, 
2001). Treating the cancer patient is always about treating the individual; 
furthermore, individual physicians make the decisions to some extent qualitatively. 
This stresses the importance of assessing HRQoL on a more individual basis and of 
gaining understanding of the individual meanings encountered by the patient when 
receiving cancer treatment.  Being able to rise to the challenge of more 
individualised research in cancer clinical trials, HRQoL research has at least 
complemented the current HRQoL research with more individualised methods.  
Therefore, adapting phenomenology, qualitative research, and more structural 
theories of human behaviour are essential. In phenomenological psychology, 
HRQoL can be studied using descriptive or interpretive techniques, including 
disciplined reflection. These technigues are used to develop clear, accurate and 
believable descriptions of HRQoL. Those descriptions reveal the structure of a 
phenomenon as it is experienced, including its parts or elements (Hein & Austin, 
2001).  In structural theories, various explanatory structures are postulated. The 
explanatory  structure within an organism is comprised of relatively stable 
structures with individual, various functional mechanisms embedded in these 
structures and all relevant processes occurring within them (Vuorinen, 1981). Such 
internal systems serve to maintain an adaptive interaction between the organism 
and a continuously changing environment, offering thereby a basis for 
psychological explanation (Vuorinen, 1981). Structural theories base their 
explanation on the specifies of the mediating processes which covert the effects of 
internal and external factors. Adopting such a systemic approach to HRQoL study 
has the value of offering a theory- based understanding of individual differences. 
Hence, it provides interpretive and complementary resources for understanding the 
results gleaned from the quantitative research.        
The qualitative  (V) study was conducted to increase the understanding of the 
meaning of advanced breast cancer and its treatment for  patients’ HRQoL. In this 
study, the patients’ ability to control the illness experience manifested as the single 
most important structure of HRQoL. This point is particularly relevant in 
understanding the meanings of physical, social, emotional and role functioning as 
well as patients’ global QoL. It increases the understanding of how these meanings 
are conveyed through psychic work. These meanings and the means of fulfilling 
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them are secondary to psychic work. In order to maintain their psychic equilibrium, 
the patients are forced to change the meanings of ther physical, social, role and 
global QoL by utilising the psychic work. Consequently, actions or moments when 
enjoyment is under the person’s own control are important.  Moments during which 
they escaped the reality of illness were described as good QoL. The descriptions of 
how patients utilised feelings of autonomy differed between individuals and the 
experience being discussed; however, the analysis of several patients’ descriptions 
revealed that the extent of control of life that the patient subjectively feels is an 
important structure or meaning for patients’ HRQoL.  
The present study has some points of contact with earlier qualitative studies.  In our 
study, securing the feelings of autonomy, by at least trying to live as normal a life 
as possible, is consistent with Lam’s (2003) earlier findings on patients trying to 
regain normalcy as an important meaning. The patients in our study who 
experienced personal growth have some similarities to (Nelson, 1996) results about 
how uncertainty influences patients to focus on important aspects of life. The 
meaning of close relationships and family is concurrent with earlier studies (Arman 
et al., 2001). Patients in our study described the changes they experienced in 
emotional functioning as being  bad-tempered, feeling down, depressed and being 
less tolerant than they had been previously, and in Arman’s study, being more 
sensible and low-spirited (Arman & Rehnsfeldt, 2002). Patients with ovarian cancer 
had similar experiences to our patients reporting changes in everyday life such as 
the inability to continue employment, altered relationships with friends, the impact 
on the family, and worries about children (Howell et al., 2003a).   
This study differs from previous research in a number of respects.  In our study, 
having a sense of control was profound, not in the sense of having control over the 
course of illness but rather gaining control over the illness experience.  This differs 
from Taylor’s (1983) and Howel’s (2003b) findings of  gaining a sense of control 
over the disease .The present study explored the important meanings following the 
widely agreed key HRQoL dimensions in HRQoL research, rather than focusing on 
one meaning in particular.  
The use of empirical phenomenological analysis of data was well-grounded, since 
the purpose of the study was to focus on the individual personal experiences of the 
patients and, in doing so, to reveal structures that for participants have in common. 
One of the characteristics of empirical phenomenological research is that its aim is 
to produce the description of experience in order to understand its essential 
structure (Hein et al., 2001).  The structure defines commonality that reveals the 
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many diverse appearances of a phenomenon.  Concepts such as reliability, validity 
and generalisability are irrelevant to the evaluation of qualitative research as they 
are based on a positivistic perspective. According to Lincoln & Cuba, research 
should be evaluated on the basis of its trustworthiness, applicability as well as 
consistency and neutrality (Lincoln & Guba, 1985).The sample size of qualitative 
studies is determined not by the number of participants but by theoretical 
saturation, which is evident when no new information is discovered on the study 
phenomenon.  In this study, theoretical saturation was achieved with a sample of 18 
women.
5.2 Concluding remarks 
One way of interpreting the results of the findings of two of the studies (I & III) is 
to consider the findings according to Vuorinen’s framework for psychic self-
regulation. According to this conceptual framework, the analyses of mental 
activities are separated by defining the three types of levels of  self-regulation. This 
distinction allows one to analyse not only how somatic and social factors impose 
their influence on mental processes, but how they are utilised on the most 
fundamental level in psychic work. Our finding, that patients’ emotional well-being 
increases from the baseline, even when the treatment’s side- effects, not any 
potential treatment efficacy are in evidence, can be explained by psychic work that 
patients are forced to apply to the sense of hope that treatment offers. The finding 
of our study (II) showing that physical functioning and treatment toxicity can 
explain only 16% of the variance of global QoL seems plausible according to the 
view that somatic factors are utilised in psychic work, in order to maintain psychic 
equilibrium. This framework explains the findings that the majority of studies 
reported no significant HRQoL differences between treatment groups in advanced 
breast cancer trials  (Bottomley et al., 2002). In terms of QoL research and clinical 
decision making, zero-difference results between treatments should be treated with 
caution as they may well be due to the standard instrument’s limitations in catching 
important meanings of HRQoL. Future research in HRQoL should be 
complemented with more individualised methods, and research questions should be 
posed more in the direction of why patients experience their HRQoL in the way 
they do. Hence, qualitative research methods and phenomenological psychology 
offer real potential for description and explanation of the patients’ HRQoL in a 
more meaningful way.   
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